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Cancer is a heterogeneous disease that is responsible for various molecular changes and 
pathological entities that play vital roles in its response to treatment, survival, and growth. Better 
understanding into the critical pathways and molecular events involved in cancer has enabled the 
identification of novel targets and development of anti-cancer therapies. In this study, two 
enzymes that have been shown to be involved in different stages of cancer were used, namely 
cathepsin B and Hsp90. The main aim of this study was to employ integrated in-silico 
approaches to study inhibitory routes of these enzymes to develop novel anti-cancer agents.  
Cathepsin B is the most well studied of the cathepsin family as a potential therapeutic target to 
treat cancer. To accomplish practical aim 1 of this study, the Michael-acceptor type compounds 
obtained from a chemical database that irreversibly inhibit cathepsin B were investigated. 
Validation was carried out using compounds with experimentally determined anti-cathepsin B 
activity. Four novel compounds exhibited better covalent binding affinity when compared 
against the experimentally determined prototypes. Molecular dynamics simulations were 
performed to ensure the stability of the docked complexes and to allow further analysis. Per-
residue interaction decomposition analysis provided deeper insight into the interaction themes 
with active site residues. It was found that polar and hydrophobic interactions had the highest 
contribution towards drug binding.   
Recent experimental studies have documented FDA-approved protease inhibitors involvement in 
anti-cancer activity, however, there was limited understanding to the mode of inhibition. To 
accomplish practical aim 2 of this study, the mode of inhibition of protease inhibitors against 
Hsp90 cysteine protein was investigated. The lack of an X-ray crystal structure of human Hsp90 
prompted the creation of its homology model for subsequent simulations. Two possible binding 
sites, C-terminal and N-terminal domains, were identified and considered in this study. 
Molecular docking followed by molecular dynamic simulations and post-dynamic analyses were 
performed to elaborate on the binding mechanism and relative binding affinities of nine FDA-
approved HIV-1 protease inhibitors against human Hsp90. Our findings from thermodynamics 
calculations revealed that these inhibitors were more likely to bind to the N-terminal domain (~ 
54.7 -83.03 kcal/mol) when compared to C-terminal domain. This appears to be the first account 





protease inhibitors binding to Hsp90. Information gained from this study should also provide a 
significant route map towards the design and optimisation of potential derivatives of protease 
inhibitors to treat breast cancer.  
The results obtained will serve as a powerful tool in the drug design and development process. 
However, further experimental investigations will be useful to improve our computational 
findings. 
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1.1. Background and rationale for this study 
A major problem in cancer research is the lack of new therapeutic strategies to control this 
disease. Cancer refers to an abnormal proliferation of cells, this being caused by multiple 
changes in gene expression, with the ability to invade neighboring tissues, thereby leading to 
death of the host (1, 2). Globally, cancer is regarded as a leading cause of death, constituting 
approximately 25% of all mortalities reported in Africa (3). The American Cancer Society 
reported that there is an expected increase in cancer incidences over the next 20 years due to an 
increase in the global population as well as aging (4). A better understanding of the pathological 
mechanism of cancer will assist in developing new anti-cancer drugs to reduce the disease 
burden. This thesis presents the investigation of anti-cancer drugs conducted on cancer-related 
enzyme targets, Cathepsin B and Hsp90, in order to gain insights into the discovery of potential 
anti-cancer drugs.  
Cathepsins are lysosomal peptidases that are essential for intracellular proteolysis in mammalian 
cells. Cathepsin B is one of the lysosomal cysteine proteases that belong to the papain 
superfamily, and is involved in protein degradation (5, 6). Alterations in Cathepsin B expression, 
activity, localization and protein levels lead to conditions such as cardiovascular diseases, 
neurodegenerative disorder, inflammation and cancer (6). Recent studies have reported cathepsin 
B’s involvement in cancer invasion and metastasis, making it a significant enzyme to target for 
cancer therapy (7, 8).   
Heat Shock Protein (Hsp90) is involved in activating the signaling pathways of various client 
proteins that are involved in malignancies (9). Some of these client proteins include HER2 
(promotes growth of cancer cells), AKT (activation of signaling pathways involved in cancer), 
EGFR (promotes solid tumor growth) and polymerase (directly involved in malignancies). 
Understanding the pharmacological inhibition of Hsp90 can provide a method of impeding 
various signaling pathways that are crucial for oncogenesis and malignant transformation (10).  
One approach used to reduce the drug discovery process and to advance cancer treatment is 
called “repositioning”. This refers to a situation where a new agent has been shown to be 
effective in one disease, effort is devoted to further investigate its use in various combinations 




for other disorders (11). In this study, the FDA-approved HIV-1 Protease Inhibitors (PIs) were 
investigated as potential anti-cancer drugs when interacting with Hsp90. These inhibitors have 
been shown to be involved in cancer inhibition, with the mechanisms being unclear.  
1.2. Aims and objectives of this study 
The major aim of this study was to investigate drugs as anticancer agents that target Cathepsin B 
and Hsp90. 
Given the above general aim, this study has two practical aims: 
1. To discover novel Michael acceptor-type leads that form irreversible binding with 
Cathepsin B.  
To accomplish this, the following objectives were outlined: 
1.1 To identify and acquire sets of Michael acceptor-type leads from the chemical database. 
1.2 To identify new inhibitors that form covalent inhibition with Cathepsin B using covalent 
docking approach.  
1.3 To describe the precise binding modes of covalent inhibitors. 
1.4 To determine the compound stability on the Cathepsin B active site. 
1.5 To determine active site amino acid contributions to ligand binding by performing the per-
residue energy decomposition analysis. 
2. To provide a molecular understanding of the effectiveness of the FDA-approved HIV-1 
protease inhibitors (PIs) against Hsp90. 
To accomplish this, the following objectives were outlined: 
2.1 To create a homology model due to the absence of the human Hsp90 complete crystal 
structure in the protein data bank.  
2.2 To validate the human homology model by plotting a Ramachandran plot to determine 
outliers. 




2.3 To estimate the binding affinity of the protease inhibitors against the human Hsp90 
homologue NTD and CTD.  
2.4 To determine the inhibitor’s stability on Hsp90 homologue 
2.5 To estimate the contribution of each amino acids towards the overall binding by performing 
the per-residue decomposition analysis. 
2.6 To perform a comparative study on which of the two Hsp90 terminals has better binding 
affinity for each drug. 
1.3. Novelty and significance of this study  
Despite ongoing research in anti-cancer drug development, cancer continues to receive a 
relatively low public health priority in Africa. Cancer-related morbidity and mortality rate are 
high and serious adverse effects of chemotherapy and radiation therapy contributes to an 
elevated disease burden, highlighting a need to discover and develop effective and safe anti-
cancer drugs (3, 4). Cathepsin B and Hsp90 have been shown to be effective targets for cancer 
treatments, as they are involved in various pathologies and oncogenic processes in humans, 
making it important to gain insights into their interactions with inhibitors (11, 12). This research 
study serves as a cornerstone towards providing insights into the possible design and 
development of novel anti-cancer drugs.  
1.4. Overview of this thesis 
This thesis consists of the following six chapters (including the current chapter): 
Chapter 1: In this chapter, background, aim, objectives and significance of the study are 
addressed and also provide with general outline and structure of the thesis. 
Chapter 2: This chapter gives a historic background and an overview of cancer disease and its 
treatments, and then discusses the updated statistics on the diseases’ global epidemiology. 
Important aspects of the proteins involved in the pathogenesis of cancer are also discussed in the 
concept of “the hallmarks of cancer” as described by Hannahan and Weinberg, which gives a 
clear description of the remarkable diversity of neoplastic diseases. A brief discussion on 
targeted therapy is presented and the essential drug targets, cathepsin B and Hsp90, selected as 




the main focus of this research, are described in detail. This includes: their detailed structures 
(including their active sites) and functions; their pathological pathways that contribute to cancer, 
and also their general mechanism of action. 
Chapter 3: This chapter presents an introduction to, and application of computational chemistry, 
different molecular modeling and molecular simulation techniques. An overview of the 
theoretical descriptions of the computational methods is provided and a description of several 
computational tools used in this study then follows. These methods include: molecular dynamics 
(MD) simulations, molecular mechanics (MM), molecular docking and binding free energy 
calculations.  
Chapter 4: (Published work– this chapter is presented in the required format of the journal 
and is the final revised accepted version) 
This research paper is titled “In-silico identification of irreversible cathepsin B inhibitors as anti-
cancer agents: virtual screening, covalent docking analysis and molecular dynamics 
simulations.”, and was published in the Journal of Combinatorial Chemistry & High Throughput 
Screening. It addresses Aim 1 and Objectives 1.1 to 1.5 of this study.  
The chapter presents a comparative study of Cathepsin B and its inhibitors with several 
computational techniques being adopted for optimising the results. A ‘ZINC’ database search for 
compounds with Michael-acceptor like features was carried out. Covalent docking was 
conducted for compounds that showed better binding to Cathepsin B. The final ‘hit’ compound 
with the highest covalent binding affinity was selected for further analysis using MD 
simulations. To verify the docking results, binding free energy calculations were carried out. Per-
residue decomposition analysis was also performed to determine the most interactive amino acid 
residues within the active site.  
 
Chapter 5: (Submitted work – this chapter is presented in the required format of the 
journal and is the final revised submitted version) 
This is a research paper from this study titled “Could the FDA-approved anti-HIV drugs be 
promising anticancer agents?” and it addresses Aim 2 and Objectives 2.1 to 2.6.  




It presents the comparative study on Hsp90 with FDA-approved HIV-1 protease inhibitors that 
have shown inhibitory effects on cancer. Several computational methods were adopted for 
optimising the results. Due to the absence of the complete human Hsp90 crystal structure, a 
model from the protein sequence was built using the relevant crystal structure with PDB Codes: 
2CG9, 3PRY and 3HJC as reference templates. Molecular docking was carried out on all the 
FDA-approved PIs to build Hsp90/HIV-1 PIs complexes. MD simulations to determine the 
compounds stability within a human Hsp90 homologue active site and binding free energy 
calculations were also performed. Per-residue decomposition analysis was also performed to 
determine the most interactive amino acid residues within the active site. Other post-dynamic 
calculations were performed on both domains of human Hsp90 homologue. 
Chapter 6: This chapter answers the research question, and addresses the study aim by 
reviewing the aim findings from the two sub-aims. It presents the study limitations, 
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2. Introduction to Cancer and its drug targets 
This chapter briefly provides an overview on the historical background of the diagnosis and 
treatments of cancer. Problems encountered during chemotherapeutic drug development are 
briefly discussed. It then provides insights into the structural and functional properties of the 
different cancerous drug targets used in this research. 
2.1. Background 
Cancer is ranked as the second highest cause of death worldwide, the increasing burden of cancer 
in developing countries is attributed to numerous factors, such as population aging and growth 
and, cancer-associated lifestyle factors (smoking, physical inactivity, and unhealthy diets) (1-3). 
In people redisposed to the negative consequences of these factors, cancers can manifest in 
various forms, including tumours, leukemia, sarcomas, Hodgkin disease and non-Hodgkin 
lymphoma.  
Malignant tumors are cancerous growths that invade nearby tissues and can spread to other parts 
of the body, with example of tumors including the brain, lungs, breast, prostate, skin, and colon 
(4). Breast cancer is the most commonly diagnosed type of cancer globally, with an expected 
20% increase in related deaths in the next 10 years (5-7). Global increases in newly diagnosed 
cancer cases and deaths remain unchecked (5).  
There has been a paradigm shift in drug development, from empirical cytotoxic approach 
identified by screening a variety of natural and synthetic compounds, to therapies that act at 
specific molecular targets (8-10). In recent decades, an increased understanding of genetics and 
molecular biology of cancer has facilitated the identification of potential molecular targets for 
anticancer drug discovery and development (11, 12). The main purpose of the target-based drug 
discovery approach is to develop agents that block the pathogenic mechanism responsible for 
malignant transformation (13), as well as to discover etiologic agents that demonstrate minimal 
adverse effects on normal cells (9). However, for the majority of commonly known classified 
cancers, there are no specific etiologic agents available, thereby prompting further investigation 
(9). Hanahan and Weinberg described the functional, molecular and biological traits that 




differentiate tumor from normal cells as the ‘hallmarks of cancer’ (14, 15). This understanding 
has resulted in the development of several compounds to treat advanced malignancies with 
specific molecular targets (14, 16).  
2.2. The Hallmarks of Cancer 
Ongoing cancer research has not only enriched understanding the complexity of this disease, but 
has also revealed the dynamic alterations in a cancerous genome (15). Despite the rapid 
advancements in research, it remains difficult to develop effective drugs due to the complexity of 
cancer cells and the tumor microenvironment (14, 17). Hannahan and Weinberg’s (15, 18) 
concept of the ‘hallmarks of cancer’, provides with deeper insights into the traits of remarkable 
diversity of neoplastic diseases and have assisted with developing cancer drugs for particular 
molecular targets that incorporate these hallmarks (19). Figure 2.1 provides some examples of 
drugs that have been developed to target ‘the hallmarks of cancer’. In addition, the ‘hallmarks of 
cancer’ have served as a powerful guide for translational research that aims to improve and 
develop early detection, screening, and treatment, and to enhance the quality of life and well-
being of cancer patients (20). 
Hannahan and Weinberg indicate that: a. normal cells progressing towards a neoplastic state 
acquire progression of several hallmark abilities, and b. the multistep process of human tumor 
pathogenesis may be rationalized by emerging cancer cells to acquire cancerous traits that 
facilitate tumorigenesis and eventually malignancy (15, 18). The hallmarks or traits are mainly 
the acquired capabilities that enable cancer cells survival, proliferation and spread (17, 18). 
These hallmarks include sustaining proliferative signaling, insensitivity to growth suppressors, 
an ability to evade apoptosis, limitless replicative potential, sustained angiogenesis and an ability 
to metastasize (15, 18, 19). Progresses in the past decade have included four biological 
capabilities, namely, genome instability, tumour-promoting inflammation, reprogramming of cell 
bioenergetics and an ability to escape immune destruction (18, 20). These hallmarks are 









Figure 2.1: The hallmarks of cancer with examples of therapeutics targeting each hallmark 
(18). 
2.2.1. Sustaining proliferative signaling 
During growth and differentiation of normal cells, cell proliferation is controlled to ensure that a 
homeostatic cell number is achieved, thereby resulting to maintaining a normal tissue 
architecture and function (18). Normal cells require mitogenic growth signals to move from a 
state of rest to a state of active proliferation, which is generally produced by neighboring cells 
(14, 15). Transmembrane receptors transmit signals into the cells by binding to different classes 
of signaling molecules such as cell-to-cell adhesion interaction molecules, diffusible factors and 
extracellular matrix component (15). Studies have shown that without such stimulatory signals, 
proliferation of any type of normal cells cannot occur (14, 15, 21). However, tumor cells 
continue to proliferate even in the absence of stimulatory signals by mimicking normal growth 
signaling (39). These imitated signals are produced by oncogens that are involved in most of the 
cellular signaling pathways (14, 18, 22, 23). One of the signals produced by oncogens is the 




phosphatidylinositol-3-kinases (PI3K)/AKT pathway, which is responsible for promoting cell 
growth, proliferation, survival and migration (14, 24, 25). Inhibiting the biological function of 
(PI3K)/AKT and the self-sufficiency of its growth signals has shown important effects in cancer 
regimens (26). 
2.2.2. Insensitivity to growth suppressors 
Apart from the hallmark ability to sustain proliferative signals, cancer cells have also mastered 
the ability to evade powerful mechanisms that negatively regulate their proliferation (3). In 
normal tissues, several growth arrest signals function to prevent their proliferation, thus 
maintaining cellular quiescence and homeostasis (15, 18). Limitations in cell growth and 
proliferation are achieved by tumor suppressor genes that encode the retinoblastoma (RB) family 
of proteins and cyclin-dependant kinases (CDKs) (14, 27, 28). Cancer cells evade RB signals, 
either by gene mutation or altered expression of cyclin-dependant kinases (14, 26). As a result, 
CDK inhibitors that regulate cyclin function are often found in malignancy (26).  
2.2.3. Resisting apoptosis 
Normal cells do not only maintain cell homeostasis through proliferation but also through 
apoptosis, which is a process of programmed cell death that takes place in order to control the 
organism’s cell growth and development (14, 29, 30). Alternatively, tumor cells have evolved 
numerous strategies to resist or circumvent apoptosis (14, 31). The most common strategy in 
which tumor cells evade apoptosis is through the loss of the TP53 tumor suppressor gene 
function. This encodes the p53 tumor suppressor gene responsible for regulating the cell cycle, 
which then functions as a tumor suppressor (18). Tumor cells also increase the expression of 
antiapoptotic regulators, namely, Bcl2 and Bcl-xL, by the downregulation of pro-apoptotic 
factors such as Bax, Bim and Puma (18, 31). Various approaches to reversing apoptosis are 
currently under development and are aimed at magnifying chemotherapeutic effects (26, 32).  
2.2.4. Limitless replicative potential 
Numerous studies have demonstrated that normal cells carry an intrinsic, stand-alone program 
that allows them to limit their proliferation and multiplication (14, 15). Some cell populations 
enter a “senescence” state (alive but non-proliferative state) after undergoing a certain number of 
cell divisions or a “crisis” leading to cell death (14, 18, 33). Rare cells that survive crisis show 
unlimited replicative potential, thus becoming immortilised (a characteristic of established cell 




line due to their ability to proliferate without evidence of senescence and crisis) (15, 20). 
Telomerase, discovered by Greider and Blockburn, is an enzyme that synthesizes DNA 
telomeres and maintains DNA molecule stability (14, 33). In the absence of this enzyme 
telomerase becomes shorter, thus preventing DNA replication leading to cell cycle arrest or death 
(14, 34). Tumor cell, on the other hand, enable replicative immortality by two mechanisms: a. by 
an increase in the expression of telomerase, and b. by activating an alternative recombination-
based telomere maintenance mechanism, which is less common (14, 18, 19). As a result, drugs 
targeting telomerase are said to have an increased specificity and a reduced toxicity to normal 
tissue (26, 35).  
2.2.5. Inducing angiogenesis 
During embryogenesis, new blood vessels are developed from the existing ones (angiogenesis) to 
supply oxygen and nutrients that are crucial for cell function and survival (15, 18). Once the new 
tissues are formed, the process of angiogenesis is adequately and transitory regulated (14, 15, 
18). In contrast, tumor cells require angiogenesis early during the multi-step development of 
invasive cancers, thereby ensuring that its oxygen and nutrients needs are met (15, 18, 26). 
Tumor vasculature is characterized by enlarged vessels, microhemorrhaging, irregular blood 
flow, leakiness, excessive vessel branching and an abnormal level of endothelial cell 
proliferation and apoptosis (18, 36, 37). Angiogenesis-induced progression of micrometastases to 
lethal macrometastases is said to be the major cause of death in cancer patients (19). Drugs 
targeting angiogenesis have drastically improved in the last 30 years and most of these drugs 
inhibits pro-angiogenic factors such as VEGF, EGF, PDGF and interleukins (14, 19, 38, 39). 
2.2.6. Activating invasion and metastasis 
Metastasis is a process by which tumor cells move away from the primary organ, invade adjacent 
tissues and travel to distant sites, via hematogenous or lymphatic circulation, where they succeed 
in finding new colonies (15, 40). This acquired capability enables tumor cells to invade and 
metastasize to new terrain where there are sufficient space and nutrients (15). This is due to 
alterations in the cancer cell shape and their clinging to other cells or to the extracellular matrix 
(ECM) (18). E-cadherins, a key cell-to-cell adhesion molecule, is downregulated in human 
carcinomas, thus cell quiescence cannot be maintained (18, 26). Most drugs created to inhibit 




metastasis are currently in clinical trials, with none having been approved by USA Food and 
Drug Administration (FDA) (14). 
2.2.7. Genome instability and mutation 
The above-mentioned hallmarks depend mainly on the successions of genomic alterations of 
neoplastic cells (18). For example, the acquired capability of evading growth suppressors is 
solely dependent on DNA methylation and histone modifications (41, 42). However, some 
genomic alterations are triggered by nonmutational alterations that affect the regulation of gene 
expression (43). “Housekeeping” or “maintenance” genes are those linked to genetic instability 
development, and are responsible for detecting, preventing and repairing DNA damage (14, 44). 
One of the well-studied genes that senses single stranded DNA damage and aids in its repair in 
neoplastic cells is the PARP1 gene (45). Drugs known as chemotherapy-enhancing agents have 
been developed for PARP inhibition (26, 45-47).  
2.2.8. Tumor-promoting inflammation 
Progress in hallmark cancer research has demonstrated that tumor-associated inflammatory 
response has the unexpected effect of promoting tumorogenesis and progression on developing 
neoplasia (18). It has been stated that inflammation play essential role to numerous hallmark 
capabilities by providing bioactive molecules to the tumor microenvironment (48). These 
include, invasion and metastasis, survival factors that limit cell death, extracellular matrix-
modifying enzymes for angiogenesis, proangiogenic factors, and growth factors that enables 
proliferative signaling (26, 49). In addition, inflammatory cells also release actively mutagenic 
chemicals (reactive oxygen species, ROS) to nearby tissues, resulting in intensified malignancy 
(18, 49). 
2.2.9. Reprogramming energy metabolism  
Under aerobic conditions, normal cells undergo the process called glycolysis where glucose is 
converted first to pyruvate in the cytosol and then to carbon dioxide in the mitochondria under 
anaerobic conditions (18). This is different to cancer cells, which limit their metabolism to 
glycolysis in the process called the “Warburg effect” (50, 51). The discovery by Warburg was 
that: even in the presence of oxygen (aerobic condition), cancer cells constantly enhance their 
glucose metabolism, and that this “aerobic glycolysis” involves alterations in ATP production by 
oxidative phosphorylation even in quiescent and differentiated cells (14, 51, 52). Tumor cells 




depend on glycolysis for cell growth and division to ensure that all their metabolic requirements 
are met (18, 53). This hyperglycolytic state of tumor cells has shifted the focus of anticancer 
drug development into drugs that inhibit glycolysis mediated by 2-deoxy-D-glucose (2DG) (53). 
2.2.10. Evading immune destruction 
The theory of immune surveillance suggests that the immune system recognizes and eliminates 
numerous incipient cancer cells (18, 54). Solid tumors that develop have the ability to limit this 
immune recognition, thereby evading eradication (55). Strategies that enable tumor cells to evade 
immune destruction are: promoting cell recognition errors by Natural Killer cells (NK), physical 
exclusion from the immune cells at the tumor site, and adapting poor immunogenicity by 
reducing major histocompatibility complex (MHC) expression (14, 56). Passive immunization, 
monoclonal antibodies and cytokine administration have been introduced to activate antitumor 
immunity from the observation that a wide variety of proteins expressed by tumors can be 
recognized by the immune system (57).  
2.3. Targeted therapy 
Although the principal options for cancer regimens (i.e. surgery, radiotherapy and chemotherapy) 
have proved successful, the beneficial effects pose several health risks to these patients (58, 59). 
Some of these include: ineffective therapeutic drug concentrations to tumor tissues, high dose 
requirements, life threatening side-effects due to non-specificity of anticancer agents and 
multiple drug resistance (MDR) development that triggers cross-resistance (59-61). A deeper 
understanding of molecular biology and genetics of cancer has allowed for revolutionary changes 
in drug development tactics, whereby novel cancer drugs have been developed to interact with 
specific molecular targets (61-64). Targeted therapy enhances patient survival rate due to the 
high therapeutic index and a dose below the maximal threshold required for optimally effective 
treatments (60-62). Peptides, monoclonal antibodies, vitamins (folic acid, aptamers, lectins), 
hormones and growth factors are examples of compounds utilized as  targeting moieties in 
targeted cancer therapy (58, 65). The basic principle of drug targeting involves classifying these 
substances by their method of reaching the targeted tissue, leading to the distinction between 
passively and actively targeted therapy (42, 58) as discussed below: 




a.  Passive Targeting 
Passive targeting is a mechanism where drug or drug carrier system accumulate at a specific site 
due to physicochemical or pharmacological factors in malignant tissues (42). It relies mainly on 
the anatomical and functional differences in vasculature and permeability between normal and 
tumor tissues. As stated previously, malignant tissues show a generally heterogeneous 
distribution, have a high vascular density and larger in size, and are more permeable and leaky 
compared to the normal tissues (42, 58). This leaky vasculature enables extravasation of 
nanocarriers to the tumors. In addition, the impaired lymphatic channels in tumor tissue enhance 
the accumulation and retention of high molecular drugs, as well as the availability of 
chemotherapy for cell death (42, 58), this phenomenon being referred to as the enhanced 
permeability and retention (EPR) effect.  
b. Active Targeting 
Active targeting involves the expression of receptor and antigen by cancerous cells as compared 
to normal cells (42). For example, folate receptors and some surface bound antigens, such as 
prostate-specific membrane antigens (PSMA), which are uniquely and highly expressed in 
cancerous cells compared to normal cells. Active targeting employs a targeting moiety called a 
ligand to achieve surface conjugation of nanoparticles with particular targets, thereby increasing 
the specificity and affinity for surface receptor or antigen expression on specific tissues (42, 58). 
It has been stated that, active targeting improves drug delivery localization to the tumor and aids 
in drug delivery system uptake by endocytosis (42). Some examples include, aptamers, peptides, 
sugar molecules, antibodies and nanobodies (42, 58).    
2.4. Cancer drug targets  
While there are a number of cancer drug targets, only those that were used in this study, due to 
their involvement in various pathologies and oncogenic processes in humans, are discussed. 
These include the two drug targets, namely: Cathepsin B and Heat shock protein 90 (Hsp90), 
each of which will be reviewed with respect to their structure, active site and mechanism of 
action. 
2.4.1. Cathepsin B 
Cathepsin B is the most abundant lysosomal cysteine protease that belongs to the papain family 
of enzymes and it is involved mainly in intracellular protein degradation (66). It is also involved 




in a variety of physiological and pathological processes such as bone resorption, antigen 
processing, cartilage proteoglycan breakdown, intracellular protein turnover and malignant 
progression of tumors (67-69). Cathepsin B is synthesized as an inactive proenzyme, which is 
then translocated to the lysosomes for modification and maturation into active enzyme (70). A 
mature Cathepsin B exhibits optimal activity at slightly acidic pH and it becomes inactivated at 
neutral or slightly alkaline pH due to irreversible denaturation (66, 69). A remarkable feature of 
Cathepsin B that makes it distinct from other cysteine peptidases is its ability to acts both as an 
endo- and an exopeptidase (peptidyldipeptidase) (66, 67).  
Recent studies have shown that Cathepsin B is associated with invasive and metastatic 
phenotypes in cancers. This association is reported to be a result of the abnormal regulation of 
Cathepsin B causing cells to acquire an oncogenic characteristic (71, 72). In addition, 
overexpression of Cathepsin B has been observed in various malignancies including breast, lung, 
prostate, colorectal and brain cancer (71). As a result, targeting Cathepsin B will have significant 
clinical relevance in cancer therapy (73). 
2.4.1.1. Structure of Cathepsin B 
The matured form of Cathepsin B is a 30kDa bilobal protein comprised of both one light and 
heavy chains. The light chain comprises residues Leu1-Asp47 from the amino acid terminal and 
the heavy chain comprises Val50-Asp254 from the carboxyl terminal (69). Located between the 
two lobes are the active site and the substrate binding cleft (Figure 2.2). In addition, human 
Cathepsin B also possesses six disulfide bridges that are confined to half the amino-terminal of 
the molecule (66). 
Numerous X-ray crystallographic studies have shown that Cathepsin B is unique amongst other 
cysteine peptides, as it consists of a flexible structural element known as the “occluding loop”, 
which consists of Ile105-Pro126 amino acid residues. The open and closed conformations of the 
loop enable the endo- and exopeptidase characteristics of Cathepsin B, respectively (67, 68).  





Figure 2.2: The structure of Cathepsin B showing the occluding loop (red), the active site 
cleft within the light chain (pink) and heavy chain (blue). 
2.4.1.2. Cathepsin B active site  
As illustrated in Figure 2.3, the crucial active site residues of Cathepsin B are Cysteine 29 
(Cys29) and Histidine 199 (His199). Cysteine 29 is located in the middle region within the 
occluding loop that catalyses the peptide bond cleavage on the left lobe, which then interacts 
with His199 on the right lobe (69). It has been reported that the Cys29 thiole and imidazole side 
chains and His199 form an ion pair in a pH ranging from 4.0 to 8.5, respectively (74). 
Furthermore, the occluding loop residues, His110 and His111, regulate the substrate access to 
Cathepsin B active site which then binds to the carboxylic group of the C terminal of the 
substrate. These residues, His110 and His111, are also responsible for Cathepsin B stabilization 
(67).       
 
Figure 2.3: The active site cleft of Cathepsin B showing Cys29 and His199 amino acid 
residues in red. 




The dual mechanism of Cathepsin B is its ability to exhibit both endopeptidase and exopeptidase 
activities. When acting as an endopeptidase, Cathepsin B cleaves the internal peptide bond 
through the interaction between Cys29 and His199 with a broad specificity and preference of 
basic residues or phenylalanine (66, 74). Cathepsin B accepts an arginine due to the availability 
of a glutamic acid (E245) that is situated at the top of the binding pocket (74). When acting as an 
exopeptidase (peptidyldipeptidase), Cathepsin B removes dipeptides from the C-terminus of 
proteins and peptides. This activity occurs at a low pH which holds the occluding loop at a 
closed conformity at the substrate binding cleft (68).  Consequently, the end of the active site 
cleft is partially blocked by the loop, thereby allowing the positively charged imidazole group 
(His111) to accept a negative charge associated with the C-terminal (74). 
2.4.2. Heat shock protein 90 (Hsp90) 
Heat shock proteins (HSPs) are highly conserved molecular chaperones that play essential roles 
in protein folding, intracellular disposition and proteolytic turnover in response to stress, thereby 
serving as central integrators of cellular homeostasis (75-77). These molecules were first 
discovered in 1962 in Drosophila melanogaster as proteins stimulated by thermal stress, and 
then later shown to be excited by other stressful cellular conditions, such as hypoxia, 
inflammation, radiation and toxins. HSP regulation occurs through the action of heat shock 
transcription factors (HSF), with mammalian forms being classified into five families according 
to their molecular weight: Hsp40, Hsp60, Hsp70, Hsp90 and a small HSP such as Hsp27 (76). 
Among these families of chaperoning proteins, Hsp90 has been found to be the most abundant 
cellular chaperon protein.  
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that is crucial for 
maintaining, activating and stabilizing numerous client proteins in eukaryotes. Most of these 
client proteins are involved in signaling pathways such as signal transduction, protein 
degradation and intracellular transport (78, 79). Hsp90 client proteins include HER2, AKT, 
EGFR, SRC, CRAF, ABL, FLT3, MET, BRAF, telomerase (directly involved in malignancy), 
androgen and estrogen receptor and hypoxia-inducible factor ((HIF)-1α). However, there is a 
variety of client proteins that have been identified and the list is continuously updated (76). To 
achieve its function, Hsp90 form a multicomponent complex with a large group of co-factors, 
known as co-chaperones, to facilitate recognition and activation of client proteins (78). This 




Hsp90/co-chaperone complex aids regulation of ATPase conformational changes. With the 
identified co-chaperones including Cdc37, Hsp40, Hsp70, p23 and Hop (Hsp40 and Hsp70 are 
organizing proteins) (80, 81). As a result, Hsp90 has appeared as an interesting target for cancer 
therapy due to its involvement in activating various signaling pathways involved in malignancy. 
2.4.2.1. Structure of Hsp90 
Hsp90 exists in all eukaryotic cells and consists of four members: the stress-induced Hsp90α, 
Hsp90β that is constitutively expressed, glucose-related protein 94 (GRP94) located in the 
endoplasmic reticulum and mitochondrial TNF receptor-associated protein 1 (TRAP1) (81). 
Structurally, Hsp90 is a homodimer consisting of three flexibly linked domains: firstly, an N-
terminal ATP-binding domain (NTD or ND), where ATP binding and hydrolysis take place for 
the chaperoning activity of Hsp90 (refer to Figure 2.4). The ATP binding at this site constitutes 
to the conformational dynamic state of Hsp90, and also controls its interaction with client 
proteins and chaperones (75, 82, 83). Secondly, is the middle domain (MD), which contributes to 
client protein and chaperone binding to Hsp90 (77, 78, 83). Moreover, there is a highly charged 
linker that connects the NTD to the MD, which is 80 residues long in human Hsp90β (75).  
Lastly, the C-terminal dimerization domain (CTD or CD) is involved in Hsp90 dimerization and 
is also reported to contain an MEEVD motif required for TPR binding (78, 80, 83).   
 
Figure 2.4: The structure of Hsp90 (Hsp90α and Hsp90β both with ATP), showing the NTD 
(pink), MD (blue) and the CTD (cyan). 




2.4.2.2. Hsp90 active site 
The NTD entails an ATP binding site composed of the well-conserved residues Ser108, Phe133, 
Asp97, Cys53 and Met93 for Hsp90 ATPase activity (84). Most of the pharmaceutical studies 
have focused on developing drugs that inhibit ATPase activity for cancer therapy, an approach 
that has shown some success (85, 86). The MD is reported to contain catalytic residue Arg391 
that is essential for forming ATPase site, and is also involved in ATP hydrolysis (78, 81, 83). 
The CTD is composed of the well conserved residues namely, Cys590, Gly540, Trp598, Thr537, 
Ser594 and Ile590, thereby permitting the CTD dimerization activity. In addition, while the far 
end of the CTD was implicated as an alternative ATP binding site, there is no structural evidence 
for this suggestion (78, 83). 
2.4.2.3. Conformational dynamics of Hsp90 
ATP binding to Hsp90 triggers conformational changes that are required to facilitate the 
chaperoning activity of Hsp90. This forms a multicomplex structure with Hsp40, Hsp70, Hop 
and Cdc37 co-chaperones, thereby aiding client protein recognition (81). In this ‘open 
conformation’ state, Hsp90 becomes a mature complex, ready to perform its functions of client 
protein folding and stabilization (81). As mentioned earlier, the MD interacts with the co-
chaperone aha1, and contributes to ATP hydrolysis to ADP and p23 binding. Consequently, the 
binding of the p23 co-chaperone to the Hsp90/client protein complex leads to client protein 
refolding and release (76, 81). Hsp90 then reaches a ‘closed conformation’ state, where N-
terminal domains are dimerized (Figure 2.5). The released Hsp90 and co-chaperones will 
participate in the next ATPase cycle, while client proteins are degraded by ubiquitin proteasomes 
(76).  





Figure 2.5: General mechanism of the ATPase cycle of Hsp90 showing an open and a closed 














1. Anand, P., Kunnumakara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, S. T., Lai, 
O. S., Sung, B. Y., and Aggarwal, B. B. (2008) Cancer is a Preventable Disease that 
Requires Major Lifestyle Changes, Pharm. Res. 25, 2097-2116. 
2. Vedham, V., Divi, R. L., Starks, V. L., and Verma, M. (2014) Multiple Infections and 
Cancer: Implications in Epidemiology, Technol. Cancer Res. Treat. 13, 177-194. 
3. Vineis, P., and Wild, C. P. (2014) Global cancer patterns: causes and prevention, Lancet 
383, 549-557. 
4. Carroll, K. K. (1998) Obesity as a risk factor for certain types of cancer, Lipids 33, 1055-
1059. 
5. Are, C., Rajaram, S., Are, M., Raj, H., Anderson, B. O., Swamy, R. C., Vijayakumar, M., 
Song, T., Pandey, M., Edney, J. A., and Cazap, E. L. (2013) A review of global cancer 
burden: Trends, challenges, strategies, and a role for surgeons, Journal of Surgical 
Oncology 107, 221-226. 
6. DeVita, V. T., and Rosenberg, S. A. (2012) Two Hundred Years of Cancer Research, N. 
Engl. J. Med. 366, 2207-2214. 
7. Patel, J. D., Krilov, L., Adams, S., Aghajanian, C., Basch, E., Brose, M. S., Carroll, W. 
L., de Lima, M., Gilbert, M. R., Kris, M. G., Marshall, J. L., Masters, G. A., O'Day, S. J., 
Polite, B., Schwartz, G. K., Sharma, S., Thompson, I., Vogelzang, N. J., and Roth, B. J. 
(2014) Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From 
the American Society of Clinical Oncology, Journal of Clinical Oncology 32, 129-+. 
8. Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., and Workman, P. (1999) 
Anticancer agents targeting signaling molecules and cancer cell environment: Challenges 
for drug development?, Journal of the National Cancer Institute 91, 1281-1287. 
9. Giang, I., Boland, E. L., and Poon, G. M. K. (2014) Prodrug applications for targeted 
cancer therapy, The AAPS journal 16, 899-913. 
10. Kummar, S., Gutierrez, M., Doroshow, J. H., and Murgo, A. J. (2006) Drug development 
in oncology: classical cytotoxics and molecularly targeted agents, Br. J. Clin. Pharmacol. 
62, 15-26. 
11. Geromichalos, G. D. (2007) Importance of molecular computer modeling in anticancer 
drug development, J. Buon 12, S101-S118. 




12. Saijo, N., Tamura, T., and Nishio, K. (2003) Strategy for the development of novel 
anticancer drugs, Cancer Chemother. Pharmacol. 52, S97-S101. 
13. Fox, E., Curt, G. A., and Balis, F. M. (2002) Clinical trial design for target-based therapy, 
Oncologist 7, 401-409. 
14. Bailon-Moscoso, N., Romero-Benavides, J. C., and Ostrosky-Wegman, P. (2014) 
Development of anticancer drugs based on the hallmarks of tumor cells, Tumor Biol. 35, 
3981-3995. 
15. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer, Cell 100, 57-70. 
16. Saijo, N., Tamura, T., and Nishio, K. (2000) Problems in the development of target-based 
drugs, Cancer Chemother. Pharmacol. 46, S43-S45. 
17. Floor, S. L., Dumont, J. E., Maenhaut, C., and Raspe, E. (2012) Hallmarks of cancer: of 
all cancer cells, all the time?, Trends Mol. Med 18, 509-515. 
18. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of Cancer: The Next Generation, 
Cell 144, 646-674. 
19. Siddiqa, A., and Marciniak, R. (2008) Targeting the hallmarks of cancer, Cancer Biol. 
Ther. 7, 740-741. 
20. Hainaut, P., and Plymoth, A. (2013) Targeting the hallmarks of cancer: towards a rational 
approach to next-generation cancer therapy, Curr. Opin. Oncol. 25, 50-51. 
21. Engelman, J. A. (2009) Targeting PI3K signalling in cancer: opportunities, challenges 
and limitations, Nat. Rev. Cancer 9, 550-562. 
22. Bhowmick, N. A., Neilson, E. G., and Moses, H. L. (2004) Stromal fibroblasts in cancer 
initiation and progression, Nature 432, 332-337. 
23. Cheng, N., Chytil, A., Shyr, Y., Joly, A., and Moses, H. L. (2008) Transforming Growth 
Factor-beta Signaling-Deficient Fibroblasts Enhance Hepatocyte Growth Factor 
Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion, Mol. 
Cancer Res. 6, 1521-1533. 
24. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., 
Chene, P., De Pover, A., Schoemaker, K., Fabbro, D., Gabriel, D., Simonen, M., Murphy, 
L., Finan, P., Sellers, W., and Garcia-Echeverria, C. (2008) Identification and 
characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-




kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, 
Mol. Cancer Ther. 7, 1851-1863. 
25. Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., and Evers, B. M. (2012) mTOR inhibitors 
in cancer therapy, Cancer Lett. 319, 1-7. 
26. Sledge, G. W., and Miller, K. D. (2003) Exploiting the hallmarks of cancer: the future 
conquest of breast cancer, Eur. J. Cancer 39, 1668-1675. 
27. Sherr, C. J. (1996) Cancer cell cycles, Science 274, 1672-1677. 
28. Vermeulen, K., Van Bockstaele, D. R., and Berneman, Z. N. (2003) The cell cycle: a 
review of regulation, deregulation and therapeutic targets in cancer, Cell Prolif. 36, 131-
149. 
29. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. 
H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., 
Knight, R. A., Kumar, S., Lipton, S. A., Malorni, W., Nunez, G., Peter, M. E., Tschopp, 
J., Yuan, J., Piacentini, M., Zhivotovsky, B., and Melino, G. (2009) Classification of cell 
death: recommendations of the Nomenclature Committee on Cell Death 2009, Cell Death 
Differ. 16, 3-11. 
30. Thompson, C. B. (1995) Apoptosis in the pathogenesis and treatment of disease, Science 
267, 1456-1462. 
31. Elmore, S. (2007) Apoptosis: A review of programmed cell death, Toxicol. Pathol. 35, 
495-516. 
32. Fesik, S. W. (2005) Promoting apoptosis as a strategy for cancer drug discovery, Nat. 
Rev. Cancer 5, 876-885. 
33. Hayflick, L. (1974) Strategy of senescence, Gerontologist 14, 37-45. 
34. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, 
C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. (1998) Extension of life-span by 
introduction of telomerase into normal human cells, Science 279, 349-352. 
35. Guittat, L., Alberti, P., Gomez, D., De Cian, A., Pennarun, G., Lemarteleur, T., 
Belmokhtar, C., Paterski, R., Morjani, H., Trentesaux, C., Mandine, E., Boussin, F., 
Mailliet, P., Lacroix, L., Riou, J. F., and Mergny, J. L. (2004) Targeting human 
telomerase for cancer therapeutics, Cytotechnology 45, 75-90. 




36. Baluk, P., Hashizume, H., and McDonald, D. M. (2005) Cellular abnormalities of blood 
vessels as targets in cancer, Curr. Opin. Genet. Dev. 15, 102-111. 
37. Nagy, J. A., Chang, S. H., Shih, S. C., Dvorak, A. M., and Dvorak, H. F. (2010) 
Heterogeneity of the Tumor Vasculature, Semin. Thromb. Hemost. 36, 321-331. 
38. Baguley, B. C. (2003) Antivascular therapy of cancer: DMXAA, Lancet Oncol. 4, 141-
148. 
39. Kerbel, R., and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors, Nat. 
Rev. Cancer 2, 727-739. 
40. Nguyen, D. X., Bos, P. D., and Massague, J. (2009) Metastasis: from dissemination to 
organ-specific colonization, Nat. Rev. Cancer 9, 274-U265. 
41. Berdasco, M., and Esteller, M. (2010) Aberrant Epigenetic Landscape in Cancer: How 
Cellular Identity Goes Awry, Dev. Cell 19, 698-711. 
42. Jones, P. A., and Baylin, S. B. (2007) The epigenomics of cancer, Cell 128, 683-692. 
43. Esteller, M. (2007) Cancer epigenomics: DNA methylomes and histone-modification 
maps, Nat. Rev. Genet. 8, 286-298. 
44. Vogelstein, B., and Kinzler, K. W. (2004) Cancer genes and the pathways they control, 
Nat. Med. 10, 789-799. 
45. Davar, D., Beumer, J. H., Hamieh, L., and Tawbi, H. (2012) Role of PARP Inhibitors in 
Cancer Biology and Therapy, Curr. Med. Chem. 19, 3907-3921. 
46. Drew, Y., and Plummer, R. (2009) PARP inhibitors in cancer therapy: Two modes of 
attack on the cancer cell widening the clinical applications, Drug Resist. Update 12, 153-
156. 
47. Jagtap, P., and Szabo, C. (2005) Poly(ADP-ribose) polymerase and the therapeutic effects 
of its inhibitors, Nat. Rev. Drug Discov. 4, 421-440. 
48. DeNardo, D., Andreu, P., and Coussens, L. M. (2010) Interactions between lymphocytes 
and myeloid cells regulate pro- versus anti-tumor immunity, Cancer Metastasis Rev. 29, 
309-316. 
49. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010) Immunity, Inflammation, and 
Cancer, Cell 140, 883-899. 




50. Fiaschi, T., and Chiarugi, P. (2012) Oxidative stress, tumor microenvironment, and 
metabolic reprogramming: a diabolic liaison, International journal of cell biology 2012, 
762825. 
51. Warburg, O. (1956) Origin of cancer cells, Science 123, 309-314. 
52. Wallace, D. C. (2012) Mitochondria and cancer, Nat. Rev. Cancer 12, 685-698. 
53. Aft, R. L., Zhang, F. W., and Gius, D. (2002) Evaluation of 2-deoxy-D-glucose as a 
chemotherapeutic agent: mechanism of cell death, Br. J. Cancer 87, 805-812. 
54. Vajdic, C. M., and van Leeuwen, M. T. (2009) Cancer incidence and risk factors after 
solid organ transplantation, International Journal of Cancer 125, 1747-1754. 
55. Blattman, J. N., and Greenberg, P. D. (2004) Cancer immunotherapy: A treatment for the 
masses, Science 305, 200-205. 
56. Sharma, S. V., and Settleman, J. (2010) Exploiting the balance between life and death: 
Targeted cancer therapy and "oncogenic shock", Biochem. Pharmacol. 80, 666-673. 
57. Dougan, M., and Dranoff, G. (2009) Immune Therapy for Cancer, In Annual Review of 
Immunology, pp 83-117, Annual Reviews, Palo Alto. 
58. Das, M., Mohanty, C., and Sahoo, S. K. (2009) Ligand-based targeted therapy for cancer 
tissue, Expert Opin. Drug Deliv. 6, 285-304. 
59. Tzakos, A. G., Briasoulis, E., Thalhammer, T., Jager, W., and Apostolopoulos, V. (2013) 
Novel oncology therapeutics: targeted drug delivery for cancer, Journal of drug delivery 
2013, 918304. 
60. Green, M. R. (2004) Targeting targeted therapy, N. Engl. J. Med. 350, 2191-2193. 
61. Munagala, R., Aqil, F., and Gupta, R. C. (2011) Promising molecular targeted therapies 
in breast cancer, Indian J. Pharmacol. 43, 236-245. 
62. Hemminki, A. (2002) From molecular changes to customised therapy, Eur. J. Cancer 38, 
333-338. 
63. Hoelder, S., Clarke, P. A., and Workman, P. (2012) Discovery of small molecule cancer 
drugs: Successes, challenges and opportunities, Mol. Oncol. 6, 155-176. 
64. Sikora, K. (2001) Cancer drug development in the post-genomic age, Curr. Sci. 81, 549-
554. 
65. Chari, R. V. J. (2008) Targeted cancer therapy: Conferring specificity to cytotoxic drugs, 
Accounts of Chemical Research 41, 98-107. 




66. Musil, D., Zucic, D., Turk, D., Engh, R. A., Mayr, I., Huber, R., Popovic, T., Turk, V., 
Towatari, T., Katunuma, N., and Bode, W. (1991) The refined 2.15-A X-ray crystal-
structure of human liver Cathepsin-B - The structural basis for its specificity, Embo J. 10, 
2321-2330. 
67. Illy, C., Quraishi, O., Wang, J., Purisima, E., Vernet, T., and Mort, J. S. (1997) Role of 
the occluding loop in cathepsin B activity, J. Biol. Chem. 272, 1197-1202. 
68. Schenker, P., Alfarano, P., Kolb, P., Caflisch, A., and Baici, A. (2008) A double-headed 
cathepsin B inhibitor devoid of warhead, Protein Sci. 17, 2145-2155. 
69. Song, J. X., Xu, P., Xiang, H., Su, Z. D., Storer, A. C., and Ni, F. (2000) The active-site 
residue Cys-29 is responsible for the neutral-pH inactivation and the refolding barrier of 
human cathepsin B, FEBS Lett. 475, 157-162. 
70. Turk, B., Turk, D., and Salvesen, G. S. (2002) Regulating cysteine protease activity: 
Essential role of protease inhibitors as guardians and regulators, Curr. Pharm. Design 8, 
1623-1637. 
71. Gondi, C. S., and Rao, J. S. (2013) Cathepsin B as a cancer target, Expert Opin. Ther. 
Targets 17, 281-291. 
72. Joyce, J. A., and Hanahan, D. (2004) Multiple roles for cysteine cathepsins in cancer, 
Cell Cycle 3, 1516-1519. 
73. Nomura, T., and Katunuma, N. (2005) Involvement of cathepsins in the invasion, 
metastasis and proliferation of cancer cells, The journal of medical investigation : JMI 
52, 1-9. 
74. Mort, J. S., and Buttle, D. J. (1997) Cathepsin B, Int J. Biochem. Cell Biol. 29, 715-720. 
75. Bagatell, R., and Whitesell, L. (2004) Altered Hsp90 function in cancer: A unique 
therapeutic opportunity, Mol. Cancer Ther. 3, 1021-1030. 
76. Kim, L. S., and Kim, J. H. (2011) Heat Shock Protein as Molecular Targets for Breast 
Cancer Therapeutics, J. Breast Canc. 14, 167-174. 
77. Wang, J. H., Cui, S. Z., Zhang, X. L., Wu, Y. B., and Tang, H. S. (2013) High Expression 
of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis 
in Patients with Advanced Gastric Cancer, PLoS One 8. 
78. Li, J., and Buchner, J. (2013) Structure, function and regulation of the hsp90 machinery, 
Biomedical journal 36, 106-117. 




79. Prodromou, C. (2012) The 'active life' of Hsp90 complexes, Biochim. Biophys. Acta-Mol. 
Cell Res. 1823, 614-623. 
80. Goetz, M. P., Toft, D. O., Ames, M. M., and Erlichman, C. (2003) The Hsp90 chaperone 
complex as a novel target for cancer therapy, Ann. Oncol. 14, 1169-1176. 
81. Wang, H., Tan, M. S., Lu, R. C., Yu, J. T., and Tan, L. (2014) Heat Shock Proteins at the 
Crossroads between Cancer and Alzheimer's Disease, Biomed Res. Int. 
82. Didenko, T., Duarte, A. M. S., Karagoz, G. E., and Rudiger, S. G. D. (2012) Hsp90 
structure and function studied by NMR spectroscopy, Biochim. Biophys. Acta-Mol. Cell 
Res. 1823, 636-647. 
83. Zhang, L., Fok, J. H. L., and Davies, F. E. (2014) Heat shock proteins in multiple 
myeloma, Oncotarget 5, 1132-1148. 
84. Murray, C. W., Carr, M. G., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., 
Coyle, J. E., Downham, R., Figueroa, E., Frederickson, M., Graham, B., McMenamin, R., 
O'Brien, M. A., Patel, S., Phillips, T. R., Williams, G., Woodhead, A. J., and Woolford, 
A. J. A. (2010) Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two 
Lead Series with High Ligand Efficiency, Journal of Medicinal Chemistry 53, 5942-
5955. 
85. Isaacs, J. S., Xu, W. P., and Neckers, L. (2003) Heat shock protein 90 as a molecular 
target for cancer therapeutics, Cancer Cell 3, 213-217. 
86. Powers, M. V., and Workman, P. (2007) Inhibitors of the heat shock response: Biology 
and pharmacology, FEBS Lett. 581, 3758-3769. 
87. Hartl, F. U., Bracher, A., and Hayer-Hartl, M. (2011) Molecular chaperones in protein 
folding and proteostasis, Nature 475, 324-332. 
 
 





3. Introduction to computational chemistry 
This chapter reviews the computational chemistry methods used in this study. It also provide 
with some theoretical background pertaining to computational chemistry and computer-aided 
drug design (CADD).  
3.1. Introduction 
Drug discovery and development is a very costly and a time-consuming process. The estimated 
time frame for drug discovery, from the early stages of identification to clinical trials is 10-15 
years (1). One of the main problems in computational chemistry is late stage drug failure, which 
is mainly due to absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) (2). 
Computer-aided drug design was introduced in the 1970s to help minimize drug failure 
problems, and accelerates the drug discovery process. CADD exploits computational tools and 
resources that are suitable for compound analysis, storage, management, and modelling (2-4).  
The main methods describing computational chemistry are quantum mechanics (QM) and 
molecular dynamics (MD). Quantum mechanics is a division of mechanics that explains the 
motion and interaction of subatomic particles using mathematical descriptions (5, 6). Molecular 
dynamics is a computer simulation, where atoms and molecules are allowed to interact for a 
period of time, thereby providing a view of their physical motion in the context of N-body 
simulation. One aspect of MD is molecular mechanics (MM), which is based on the use of 
classical or Newtonian mechanics to describe the physical basis behind the models (a model of a 
molecule is referred to as a collection of atoms held together by bonds) (7). In this thesis, MM 
and MD were used to predict conformational changes that may occur in the biological target 
when the ligand is bound to it. In the next sections, computational theories in MM and MD are 
described, namely, the Born-Oppenheimer, Schrodinger’s equation, potential energy surface 
(PES), and MD methodologies applied in this research study.    
3.2. The Schrödinger equation 
The Schrödinger equation is an analogue of the 2nd law of motion in classical mechanics, and 
describes the motion and behavior of systems on the atomic and subatomic levels using the wave 




function (2). The time dependent Schrödinger equation is a widely used equation that contends 
that the wavefunction does not only depends on position but also on time (8, 9). The simplest 
form of the Schrödinger equation is denoted as: 
                       Η𝜓 = Ε𝜓      Eq. 1  
Where H is the molecular Hamiltonian, 𝜓 a wavefunction (describes the state of a complete 
system) and E is the energy of the system (10, 11). The molecular Hamiltonian is a sum of the 
kinetic (T) and potential (V) energy, as shown below: 
    Η = Τ + V      Eq. 2   
The Hamiltonian is presented in detail as:  
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𝐵>𝐴𝐴              Eq. 3 
where i; j refer to electrons and A;B refer to nuclei. 
3.3. Born-Oppenheimer approximation 
The Born-Oppenheimer approximation was proposed by M. Born and J. R. Oppenheimer in 1927 
(12), and it simplifies the complexity of the Schrödinger equation. The nucleus exerts a larger 
mass in comparison to the electrons, thus the nuclei moves much slowly then the electrons. The 
Born-Oppenheimer approximation takes advantage of this phenomenon and assumes the nucleus 
to be stationary while electrons move around it (8, 9). Therefore, the approximation states that 
the Schrödinger equation (section 3.2) may be separated into an electronic and nuclear equation 
by solving the wavefunction (12), which then becomes:   
    𝜓(𝑟𝑚𝑜𝑙𝑒𝑐) = 𝜓(𝑟𝑒𝑙𝑒𝑐) (𝑟𝑛𝑢𝑐𝑙)     Eq. 4   
Eq. 1 is then presented as: 
  𝐻𝐸𝑁𝜓( 𝑟𝑒𝑙) = 𝐸𝐸𝑁𝜓(𝑟𝑒𝑙)      Eq. 5  
In HEN approximation, there is a difference between the terms due to their reliance on fixed 
nuclear position (VNN) or the reliance on the not fixed electron position (Hel). Eq. 5 includes the 
energy term EEN derived from the source that is variable due to the changing electron coordinates 
(E), and the one that is constant due to fixed nuclear coordinates (N):  




                                        (Η𝑒𝑙 + 𝑉𝑁𝑁)ψ(𝑟𝑒𝑙) = 𝐸𝐸𝑁𝜓(𝑟𝑒𝑙)       Eq. 6 
The Born-Oppenheimer approximation is better for ground state molecules than it is for the 
excited state.  From the approximated wavefunction and Hamiltonian, it is possible to obtain the 
energy of the molecule, normally called the “electron energy including nuclear repulsion”, which 
can be obtained by constructing the molecular energy curve (13). The direct result of the Born-
Oppenheimer approximation is the potential energy surface (PES).  
3.4. Potential energy surface 
Potential energy surface (PES) refers to the mathematical or graphical relationship between the 
energy of a molecule and its geometry (14). The PES concept originates from the Born-
Oppenheimer approximation, which states that the nuclei in a molecule are stationary compared 
to the electrons, thus making a molecular shape or geometry concept significant (8, 14, 15). 
Therefore, PES aids visualization and understanding of the potential energy and molecular 
geometry relationship, and provides an insight on how computational chemistry programs, locate 
and characterize structures of interest (8). The difference in the nuclei and electron motion leads 
to the so-called electronic adiabatic potential energy surfaces (14). Moreover, PES is merely a 
plot of the energy of the nuclei and electrons against the geometric coordinates of the nuclei 
(nuclei position is mostly the ground-state energy surface) (Figure 3.1) (8, 11).  
 
 





Figure 3.1: Graphical representation of a two-dimensional potential energy surface (16). 
3.5. Molecular mechanics 
Molecular mechanics is a method used to determine geometry, enthalpies, vibrational spectra and 
molecular energies of formations of stable ground state molecules (8, 9). Molecular mechanics is 
mainly based on classical models to predict the energy of a molecule as a function of its 
conformation, providing insights into the changes in cellular structure, response and function. As 
a result, this understanding offers new opportunities for disease diagnosis and treatment (8). This 
method is widely used for computing the energies and geometries of large biological molecules, 
such as proteins and nucleic acids, in which approximately 100 000 atoms can be treated and 
simulations over time scales of tens of nanoseconds can be achieved (8, 17). The total potential 
energy of a molecule is described as the sum of various interactions, namely bonded interactions, 
such as bond angles, bond length, torsion and non-bonded interactions, such as van der Waals 
and electrostatic interactions, as described in the following equation: 
                  Ε𝑡𝑜𝑡 = Ε𝑠𝑡𝑟 + Ε𝑏𝑒𝑛𝑑 + Ε𝑡𝑜𝑟 + Ε𝑣𝑑𝑤 + Ε𝑒𝑙𝑒𝑐      Eq. 7                                 
Here Etot is the total potential energy, Estr the bond-stretching energy, Ebend the bond angle-
bending energy, Etor the torsional or twisting energy, Evdw is the van der Waals forces and Eelec is 
the electrostatic forces between the non-bonded atoms.  




3.6. Force Field 
A force field refers to the combination of a mathematical equation and the associated parameters 
used to describe the dependence of the energy of a system on its atomic coordinates. The concept 
of force fields first appeared in 1960’s with the development of MM methods (18, 19). It entails 
functional form of the interatomic potential energy and a parameter set that enter into this form. 
These parameters are either obtained from semi-empirical quantum mechanical calculations or 
from experimental data such as Raman, NMR, X-ray, neutron spectroscopy and electron 
diffraction (18). The widely used functional form and parameterization protocols of biomolecular 
force fields involve AMBER, CHARM, NAMD, GROMOS and OPLS-AA. In the current study, 
AMBER force field was used, applying the General AMBER Force Field (GAFF) parameters for 
the ligand and standard AMBER force field for the enzyme (20, 21).  
3.7. Molecular Dynamics 
Due to advances in computer technology and algorithmic improvements, MD has become a 
valuable technique for computer simulating complex systems and assessing the thermodynamics 
of molecules (22, 23). Molecular dynamics simulations provide a deeper understanding of the 
nature of ligand-protein interactions, and present such interactions as ensembles that follow the 
Law of Statistical Dynamics (22, 24). MD simulations produce a dynamical trajectory for a 
system by numerically solving the Newton’s Laws of motion for the interacting species (18, 25). 
The results of the MD simulations are characterized as a trajectory that specifies particles 
position and velocity at different periods of time (26). Therefore, the Force (F𝑖) operating on a 
particle is determined as a function of time that equals to the negative gradient of potential 
energy: 
                                                             F𝑖 = 𝑚𝑖  
𝑑2𝑟𝑖(𝑡)
𝑑𝑡2
                                  Eq. 8 
Here 𝑟𝑖 (𝑡) = (𝑥𝑖(𝑡), 𝑦𝑖(𝑡), 𝑧𝑖(𝑡)) is the (𝑖) particle position vector, 𝐹𝑖 the force acting on 
(𝑖) particle at time t and 𝑚𝑖 the mass of a particle. According to the Newton’s Law of Motion, 
acceleration (α) of a particle is obtained from the force divided by a mass of a particle, as 




      Eq. 9 




The change in the velocity of a particle is equal to the integral of acceleration over a period of 
time, and the position change is equal to the integral of velocity over a period of time, as shown 
in the following equation: 
      𝑑𝑣 = ∫ 𝑎𝑑𝑡,     Eq. 10 
      𝑑𝑟 = ∫ 𝑣𝑑𝑡     Eq. 11 
As a result, the kinetic energy can be defined in terms of the velocity and momenta of the given 
particles: 





𝑖=1     Eq. 12 







𝑖=1     Eq. 13 
Therefore, the total energy of a given system is given as Hamiltonian (H), the sum of kinetic and 
potential energies, as represented in the equation below: 
      𝐻(𝑞, 𝑝) = 𝐾(𝑝) + 𝑈(𝑝)   Eq. 14 
Where, q is a set of Cartesian coordinates, p denotes the momenta of the given particles and U(q) 
is the potential energy function. The first derivatives of the positions with respect to time are the 
velocities and can be determined using the equation represented below: 
      𝑣𝑖(𝑡) =
𝑑
𝑑𝑡
𝑞𝑖(𝑡)    Eq. 15 
Where 𝑞𝑖(𝑡) is the atomic positions at a specific time, t. Based on the initial atom coordinates of 
a particular system, new positions and velocities of the atoms at a given time t and the atoms will 
migrate to these new positions. Therefore, the new conformations are generated and the 
temperature of the system is directly proportional to the average kinetic energy (25, 26). 
3.8. Approaches for estimating binding affinities 
3.8.1. Molecular Docking 
Molecular docking is a computational tool that is essential for structure-based drug design 
(SBDD). These programs are commonly used to predict the binding modes and affinities of 




small molecules (ligands) interacting with the binding site of the target protein of the known 3D 
structure (27-29). Molecular docking can be applied in binding-site identification (blind 
docking), protein-protein interaction, enzymatic reaction mechanisms, drug discovery (lead 
optimization), protein engineering, virtual screening (hit identification) and de-orphaning of the 
receptor. Docking is achieved through two correlated steps: firstly, by sampling conformations of 
the ligands in the active site of the protein, secondly, by ranking the conformations via a scoring 
function. It is highly recommended that the scoring function should rank the highest among all 
generated conformations and that the sampling algorithms should be able to reproduce the 
experimental data (30, 31). Thus, docking can be used to screen large libraries of compounds, 
rank the results, and then formulate the structural hypothesis of the ligand-receptor inhibitory 
mode, which is essential in lead optimization. The ligand-receptor binding energy is analyzed 
using molecular mechanics presented in the following equation: 
      𝐸𝑏𝑖𝑛𝑑𝑖𝑛𝑔 = 𝐸𝑡𝑎𝑟𝑔𝑒𝑡 + 𝐸𝑙𝑖𝑔𝑎𝑛𝑑 + 𝐸𝑡𝑎𝑟𝑔𝑒𝑡−𝑙𝑖𝑔𝑎𝑛𝑑   Eq. 16 
Some examples of molecular docking programs that are normally used for academic and 
commercial purposes include: Dock (27), AutoDock (32), GOLD (28), GLIDE (33), Surflex 
(34), ICM (35) and PhDOCK (34). Although these programs entail different information 
regarding the structures of component proteins, they have common computational steps, namely 
simplified and/or rigid body search, selecting the region(s) of interest, refinement of docked 
structures and selecting the best models (35). In the current studies, a quicker version of 
AutoDock and AutoDock vina (36) was used. This allowed the prediction of flexible ligands’ 
binding affinity to rigid Cathepsin B and HSP90 active sites (refer to chapter 4 and 5). In chapter 
4, we also used a CovalentDock cloud (37) to screen large libraries of compounds that form 
covalent bond with the target protein Cathepsin B.  
3.8.2. Binding free energy calculations 
Free binding energy calculations have been proven useful in the computational biochemical 
research, as they enable detailed investigation of binding affinities of small drug-candidate 
compounds. They also allow an evaluation of relative stabilities of large biomacromolecular 
structures (38, 39). The ligand-receptor binding affinities prediction serves as a cornerstone in 
the study of protein-protein interaction to structure-based drug design (40). The Molecular 
Mechanics Poisson–Boltzmann Surface Area (MM/PBSA) and Molecular Mechanics 




Generalized Born Surface Area (MM/GBSA) are efficient methods for calculating free energies 
of numerous molecular systems (41). In the current studies, MM/GBSA calculations were 
applied for confirmation of the binding energies. A brief description about free binding energy 
calculations is provided in chapter 5.  
3.8.3. Entropy calculations 
Entropy is defined as the measure of dynamics of the overall system and it forms important 
aspects of thermodynamics properties that play an essential role in the enzyme catalytic effect 
(22). The entropic contributions to the free energy reflect the strength and specificity of 
interactions between the enzyme-ligand complexes. Moreover, alterations in the binding entropy 
reveal a loss of motion due to changes in rotational and translational degrees of freedom of the 
interacting molecules (42, 43). Entropic effects have been shown to enable enzymes to speed up 
their reaction, thus these findings were essential in understanding the origins of enzyme catalysis 
(42). A recent study has shown that the entropies of activation in the enzyme and in water are 
related, with the overall catalysis being mainly due to enthalpic effects (44). The Gibb’s equation 
indicates that entropy can be calculated directly from ∆𝐺 and ∆𝐻. However, the entropy 
associated with ligand-protein binding can be expressed as the sum of numerous contributing 
effects, at a given temperature (22). The entropy is best described by the following equation: 
      ∆𝐺 = ∆𝐻 − 𝑇∆𝑆    Eq. 17 
Therefore,  
      ∆𝑆 =
∆𝐺
∆𝑆−𝑇
     Eq. 18 
Where ∆𝐺 is the free binding energy, and ∆𝐻 is enthalpy ∆𝑆 is entropy and 𝑇 is the temperature. 
3.9. Molecular Modelling methods used in this study 
3.9.1. Homology Modelling  
A deep understanding of the conformation of multi-domain proteins, DNA-protein complexes 
and large multi-protein complexes is important to explore various biological problems. To 
achieve this, nuclear magnetic resonance spectroscopy (NMR), X-ray crystallography and 
electron microscopy are used to predict the 3D structure of macromolecules. However, such 




techniques require expert-user knowledge in order to obtain accurate results (45, 46). Therefore, 
homology modelling has been considered the easier technique for predicting the 3D protein 
structure when only sequence data is available. Homology modelling builds the protein structure 
using the sequence of a protein whose X-ray structure is known as a building template. The 
success of the homology modelling is determined by the following factors: the ability to detect 
the existing homologue structure; the existence of a known homologue with known structure; the 
ability to detect the homologue and the quality of the model building.  
Programs available for homology modelling utilize different methods to produce a final model. 
Within each step of the homology modelling process, many factors affect the quality of the 
model produced and appropriate selection of the program can significantly improve the quality 
of the model (47). During the selection of homologues in homology modelling, the 
crystallographic-defined structures of protein are selected, with a resolution ranging from 1-3Å. 
In addition, High-resolution structures (with resolution values of 1Å) are highly ordered, and it is 
easy to see every atom in the electron density map, while lower resolution structures (with 
resolution of 3Å or higher) show only the basic outlines of the protein chain with inferred view 
of the atomic structure. In this research study (chapter 5), the homology model of human Hsp90 
was constructed following the steps outlined in Figure 3.2 below.  





Figure 3.2: Schematic representation of protocol followed during construction of Hsp90 
homology model. 
3.9.2. Per-residue decomposition 
Per-residue decomposition was developed to determine the specific energy contribution of each 
residue (also referred to as “hot spots”) towards ligand binding. The “hot spots” idea is that a 
number of amino acids at a binding interface make a dominant contribution to the binding 
affinity (48-50). However, further understanding of the roles of residues surrounding the “hot 
spots” is required in order to create a favorable binding environment. Per-residue decomposition 
is also used to determine bond formation in a molecule-molecule interaction (51). In per-residue 
decomposition, the contributions of rotational and translational entropies, on a residue basis, are 
expected to be insignificant or constant.  
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Cathepsin B is a cysteine protease that belongs to the papain superfamily. Malfunctions related 
to cathepsin B can lead to inflammation and cancer. Via an integrated in-silico approach, this 
study is aimed to identify novel Michael acceptors-type compounds that can irreversibly inhibit 
cathepsin B enzyme via covalent bond formation with the active site cysteine residue. Here, we 
report the first account of covalent docking approach incorporated into a hybrid ligand/structure-
based virtual screening to estimate the binding affinities of various compounds from chemical 
databases against the cathepsin B protein. For validation, compounds with experimentally 
determined anti-cathepsin B activity from PubChem bioassay database were also screened and 
covalently docked to the enzyme target. Interestingly, four novel compounds exhibited better 
covalent binding affinity when compared against the experimentally determined prototypes. 
Molecular dynamics simulations were performed to ensure the stability of the docked complexes 
and to allow further analysis on the MD average structures. Per-residue interaction 
decomposition analysis was carried out to provide deeper insight into the interaction themes of 
discovered hits with the active site residues. It is found that polar and hydrophobic interactions 
contributed the most towards drug binding. 
The hybrid computational methods applied in this study should serve as a powerful tool in the 
drug design and development process. 
Key Words: 
Cathepsin B; Michael acceptors; virtual screening; covalent docking; molecular dynamics 
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Identification of Michael acceptors as irreversible cathepsin B inhibitors. 





Cancer is considered as one of the leading cause of deaths worldwide. The American 
Cancer Society reported that cancer constitutes about 2-3% of deaths globally (1). It has been 
reported that anti-cancer drugs showed undesirable side effect on chronic therapy in patients (1). 
Therefore, there is a constant need to develop new anti-cancer drugs with higher therapeutic 
index and improved patients compliance.   
 
Cathepsins are lysosomal peptidases responsible for intracellular proteolysis in 
mammalian cells (2). These enzymes are dependent on a nucleophilic thiol group (-SH) of a 
cysteine residue for their enzymatic activity (3) (see figure 1a). They also have been found to be 
involved in biological processes related to variant diseases in humans (4). One of the lysosomal 
cysteine proteases is known as Cathepsin B and it belongs to the papain superfamily (5). 
Cathepsin B has been reported to be involved in human diseases such as cardiovascular disease, 
neurodegenerative disorder, inflammation and cancer. These diseases are due to the alterations in 
cathepsin B expression, activity, localization and protein levels (6). This enzyme has the ability 
to facilitate cell migration leading to tumor metastasis and angiogenesis resulting to cancer 
progression (2, 4, 7). As a result, design of cathepsin B inhibitors is highly considered in the 
development of therapeutic agents (2, 5). 
 
Biological studies have shown that irreversible binding occurs between the enzyme and 
several cathepsin inhibitors (4). Most of the cathepsins contain an active site cysteine residue 
(Cys29) that acts as a nucleophile and a histidine residue (His199) that acts as a general base in 
the hydrolysis of a target peptide bond in the substrate (6, 8). Compounds that contain Michael 
acceptors are considered as one of the most active irreversible cysteine protease inhibitors (9). 




These inhibitors include α, β unsaturated carbonyl derivatives, vinyl sulfones and various 
derivatives (Figure 1a). Such inhibitors bind to the active site of the enzyme forming a covalent 
bond with the catalytic thiol group of the enzyme (4).  
 
This study is designed to further identify novel Michael acceptor-type leads from 
commercial chemical database as well as to investigate their relative binding affinities and 
themes with cathepsin B by a robust integrated in-silico approach.  
Conventional virtual screening using non-covalent docking is widely used in drug 
discovery research (10-13) including the search for cathepsin B inhibitors (2, 7).  However, in 
this study, we adopted a novel and time-efficient hybrid non-covalent/covalent docking approach 
supported by molecular dynamics simulations and post-dynamics per-residue interaction 
energies calculations in order to provide more precise description of the binding modes of 
covalent inhibitors. To our knowledge, this is the first study that embarked on a hybrid non-
covalent and covalent molecular docking methodology in the virtual screening for new drug 
leads.  
 
In search for novel inhibitors, ZINC database (http://zinc.docking.org) was used. Despite 
the fact that the covalent docking approach has been validated on a wide range of biological 
systems (14), we opted to further assess the computational methods and results obtained from 
our study on a set of similar and experimentally determined molecule with known cathepsin B 
inhibitory activity (prototypes) obtained from PubChem bioassay database 
(http://pubchem.ncbi.nlm.nih.gov/pcassay) (see Methods section).  Results from the virtual 
screening were compared against the experimentally determined prototypes. 





Figure 1: (a) General mechanism of Michael addition reaction with nucleophilic groups in 
enzymes (such as cysteine). (b) Michael acceptor ligands used in this study. 
 
2. Computational Methodology 
The computational procedure adopted in this work is depicted in Figure 2 as well as explained in 
the text below. 
 





Figure 2: Workflow of the computational procedure adopted in this study. 
 
 




2.1. Enzyme acquisition 
 
The 3D complex structure of cathepsin B with its inhibitor dipeptidyl nitrile (DPN) was 
obtained from the protein data bank, PDB code: 1GMY (2). The enzyme was then isolated from 
the ligand using Molegro Molecular Viewer (MMV) software suite (www.nlcbio.com) by 
deleting subunit C from the enzyme trimer.  The free cathepsin B dimer was then used in all 
subsequent computational simulations. In a previous study, it was reported that simulation of a 
dimeric form of this enzyme is important as residues from both the first and the second protein 
chains contributed to the binding site of dipeptidyl nitrile (2).  
 
2.2. Ligands library generation 
Our search for potential inhibitors was based on electrophilic Michael acceptor-like 
compounds with known biological activity as irreversible inhibitors (prototypes) (2). It was 
found that most of these inhibitors have a thiophene-2-one or pyrol-2-one fragment in their 
chemical structure (2) (Figure 1b), therefore, we opted to use this fragment as a basis for 
pharmacophoric search.  
 
The ZINC database (http://zinc.docking.org) was used for screening of libraries of 
compounds. MarvinSketch Software (Chemaxon, http://www.chemaxon.com) was used to draw 
the template structures for the ZINC database queries based on Michael acceptor-like compounds 
as shown in Figure 1b. The ZINC database was queried for compounds with drug-like properties, 
which includes the molecular weight ranging from 300 to 500 g/mol, logP value between 1 and 
5, maximum of 5 hydrogen bond donor atoms and maximum of 10 bond acceptor atoms. This 
query gave rise to 1186 compounds hits that were downloaded as a single mol2 file. Molegro 




Molecular Viewer software (www.nlcbio.com) was then used to export the single mol2 file of 
downloaded compounds into separate mol2 files for each compound. These files were then 
converted into the pdbqt format required for docking using Raccoon software (15).  
 
2.3. Structure-based virtual screening and validation of docking protocol 
2.3.1. Non-covalent docking 
It is worth mentioning that covalent docking is more computationally exhausting and 
time consuming than conventional non-covalent docking due to the additional energy terms and 
processing steps in case of the former. Therefore, we opted to run initial non-covalent docking to 
rank the compounds library from the chemical database based on their relative binding affinities. 
To this end, all 1186 retrieved compounds, were docked into the active site of cathepsin B using 
Autodock Vina software (16). The grid box was defined using Chimera software (17) with the 
grid parameters being X= 34, Y= 42 and Z= 48 for the dimensions and X= 33.9, Y= 34.1 and Z= 
32.9 for the center grid box. The docked compounds were then ranked according to the binding 
affinities against the target protein. The top-50 ranked compounds resulted from non-covalent 
docking were then selected for further covalent docking.  
 
2.3.2. Covalent docking 
 
The theory behind covalent docking is fully explained elsewhere (14). CovalentDock 
software (14) was used to dock the top-ranked 50 compounds resulted from non-covalent 
docking into the cathepsin B enzyme.  For covalent docking, the nucleophilic center in the 
enzyme and the electrophilic sites of the ligands need to be defined. For Cathepsin B, Cys29 was 
assigned to be the nucleophilic center as evident from previous studies (2, 6, 8). CovalentDock 




automatically identifies the electrophilic sites of the mined ligands - provided that they should be 
in the correct mol2 format. The binding site center corresponding to the active site Cys29 was 
X=28.8, Y=37.2 and Z=37.2. The docked 50 ligands were subsequently ranked according to the 
covalent binding energies.  
 
Validation of docking approach 
 
To validate the covalent docking approach used in this study, the same docking procedure 
has been applied to a set of experimentally determined compounds with known anti-cathepsin B 
activity obtained from the PubChem bioassay database 
(http://pubchem.ncbi.nlm.nih.gov/pcassay) (PubChem Bioassay ID: 820).  
 
2.4. Molecular dynamics simulations 
 
Molecular dynamics simulations were performed for the top-ranked covalently docked 
ligand-enzyme complex using the Amber12 software package (18). The full scenario of 
molecular dynamics simulations is described in our previous reports (19-22), however, a brief 
description is provided herein. 
Owing to the lack of parameters needed for the ligand in the Cornell et al. force field 
(23), the missing parameters were created. Optimization of the ligands are first performed at the 
HF/6-31G* level with the Gaussian 03 package (24). The restrained electrostatic potential 
(RESP) procedure (25), is used to calculate the partial atomic charges. GAFF (26) force field 
parameters and RESP partial charges are assigned using the ANTECHAMBER module in the 
Amber12 package. Hydrogen atoms of the proteins were added using the Leap module in 




Amber12 (18).  The standard AMBER force field for bioorganic systems (ff03) (27) was used to 
define the enzyme parameters. Counter ions were added to neutralize the charge enzyme. The 
system was enveloped in a box of equilibrated TIP3P (28) water molecules with 8 Å distance 
around the enzyme. Cubic periodic boundary conditions were imposed and the long-range 
electrostatic interactions were treated with the particle-mesh Ewald method (29) implemented in 
Amber12 with a non-bonding cut-off distance of 10 Å.  Initial energy minimization, with a 
restraint potential of 2 kcal/molÅ2 applied to the solute, was carried out using the steepest 
descent method in Amber12 for 1000 iterations followed by conjugate gradient protocol for 2000 
steps.  The entire system was then freely minimized for 1000 iterations. Harmonic restraints with 
force constants 5 kcal/mol Å2 were applied to all solute atoms during the heating phase.  A 
canonical ensemble (NVT) MD was carried out for 50 ps, during which the system was gradually 
annealed from 0 to 300 K using a Langevin thermostat with a coupling coefficient of 1/ps.  
Subsequently, the system was equilibrated at 300 K with a 2 fs time step for 100 ps while 
maintaining the force constants on the restrained solute.  The SHAKE algorithm (30) was 
employed on all atoms covalently bonded to a hydrogen atom during equilibration and 
production runs. With no restraints imposed, a production run was performed for 2 ns in an 
isothermal isobaric (NPT) ensemble using a Berendsen barostat (31) with a target pressure of 1 
bar and a pressure coupling constant of 2 ps.  The coordinate file was saved every 1 ps and the 
trajectory was analyzed every 1 ps using the Ptraj module implemented in Amber12. 
 
 




3. Results and Discussion 
3.1. Hybrid Non-covalent/covalent docking 
 
Since this work was primarily aimed to investigate covalent enzyme inhibition, covalent 
docking would be the most appropriate tool to provide better description of the binding theme of 
this class of inhibitors. However, due to the fact that covalent docking is time consuming, virtual 
screening of large compound library using covalent docking approach, would be unfeasible.  To 
this end, we opted to run initial non-covalent docking to rank the 1186 compounds according to 
their binding affinities towards the target protein, and then only the best 50 docked compounds 
will be selected for a subsequent covalent docking.  
 
Validation of docking calculations 
To assess the reliability and validity of the covalent docking approach, the same docking 
protocol was performed on a set of compounds with available experimental data (IC50). The 
PubChem codes of these compounds are CID3241895, CID3243128, CID646525 and 
CID653862. As evident from Table 1, the docking results, to a great extent, are consistent with 
the experimental data - this proves that the covalent docking method applied in this study is 
reasonably reliable.  
 
The best 10 docked structures resulted from covalent docking are shown in Table 1. Also, as 
evident from Table 1, these compounds do not violate Lipinski’s rule of five, in turn, are likely to 
be orally bioavailable. 
 
 




Table 1: The ID codes, 3D structures, covalent dock binding energies and Lipinski’s rule of five 


















Experimental Compounds (PubChem codes) 
 
CID3241895 
IC50 : 0.44 
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   *CovalentDock estimated binding energy 
 
Interestingly, compounds ZINC03378824, ZINC04332083 and ZINC00477774 showed 
better binding affinities towards cathepsin B when compared to prototypes (CID3241895, 
CID3243128, CID646525 and CID653862) (see Table 1). We also noted that the two top-ranked 
compounds, ZINC03378824 and ZINC00477774 are thiophene-based inhibitors rather than 
furan-based – this is in a great accordance with experimental data (Table 1). The retrieved 
compounds library did not show any pyrrole-based inhibitors. Furthermore, the docked binding 
energies for the experimentally determined compounds (obtained from PubChem bioassay 
database) correlate well with the IC50 (Table 1).  All these findings verify that the adopted 
method is, to a great extent, reproducible and reliable. 
 




3.2. Molecular dynamic and post-dynamic analysis 
 
From our experience with molecular docking, in many occasions, we observed that even 
best docked structures are not stable enough in the enzyme active site after a short run of MD 
simulations. Therefore, we believe that, it is always important to run a reasonably long MD 
simulation to ensure that the docked complexes are stable and not docking artifacts. 
For the best-docked structure, ZINC03378824-enzyme complex, we ran 2 ns MD 
simulations. As evident from Figure 3, all-atom RSMD and the total potential energy 
fluctuations clearly verify that the system is quite stable over the MD simulations and indicate 
that the interactions with the ligand site were strong enough to maintain the ligand bonding. 
The average complex structure (Figure 4) was extracted over the 2 ns MD using ptraj 
module in Amber software (32) and then subjected to further per-residue interaction energy 
decomposition and binding forces analysis. 
 













                 
 
Figure 4: 2ns MD average structure of the top-ranked compound, ZINC03378824, 
covalently bonded to active site of cathepsin B: (A) 3D representation showing the ligand at 
the enzyme dimer interface and (B) a closer view showing the ligand covalently bonded to 
the active site Cys29. 




To further explore the crucial active site amino acid residues contributed to the binding of 
the ligand, we estimated the per-residue interaction energy decomposition using the MolDock 
scoring function (33).  This function allowed us to investigate the effect of each amino acid that 
contributed in the interactions observed between the enzyme and the hit compounds.  
 
     
Figure 5: Per-residue energy decomposition for the top-ranked compound (ZINC03378824) 
using the MolDock scoring function. 
It was observed from Figure 5 that amino acids Cys26, Cys119, Gln23, Glu122, Gly27, 
His110, His199, Ser25, Trp30 and Trp221 are interacting the most with the ligand. To provide 
better insight into the nature of the binding forces between the above-mentioned amino acids and 
the ligand, we analyzed the binding forces using MOE software (www.chemcomp.com) (Figure 
6). 
 





Figure 6: Different binding forces between the enzyme active site residues and the best hit, 
ZINC03378824. 
 
As evident from Figure 6, polar interactions are the most prominent binding forces that 
contributed to the binding of the ligand. As shown in Figure 5 and 6, residues involved in such 
interactions are Cys26, Cys119, Gln23, Glu122, Gly27, His110, His199, Ser25, Trp30 and 
Trp221. Hydrophobic interactions between the ligand and Ala200, Ala173, Trp30, Trp221 and 
Pro76 were also observed. Information gained from per-residue interaction decomposition and 
binding forces analyses, Figure 5 and 6, respectively, should assist in the design of ligands that 
can form favorable interaction with the aforementioned active site residues. 




In light of agreement of the computational results with the experimental findings, the unique 
covalent docking approach adopted in this work supported by MD simulation has proved 
successful in the prediction of the binding themes and affinities of cathepsin B covalent 
inhibitors.   
The novelty of the four hit compounds, ZINC03378824, ZINC00477774, ZINC04901668 and 
ZINC04332083 was further confirmed by the SciFinder Scholar search as these compounds have 
not been experimentally reported for cathepsin B inhibitory activity earlier. Hence, we suggest 
that these four compounds are novel scaffolds as cathepsin B inhibitors and could be potential 
anti-cancer drugs. 
Despite the fact that the integrated computational workflow presented in this work could serve as 
time-efficient powerful tool in the process of drug design and discovery of covalent inhibitors, 




In the present study, we report a unique workflow involving hybrid ligand/structure based virtual 
screening using covalent docking approach to search for novel classes of irreversible cathepsin B 
inhibitors based on Michael acceptors-like structures. Furthermore, the current work has 
provided insight into the active site residues involved in ligand binding through per-residue 
interaction energy decomposition and binding forces analysis. Results showed that polar 
interactions between the ligand and active site residues have contributed the most towards the 
ligand binding. Also, hydrophobic interactions played a role in drug binding.  




However, further experimental investigations are still required to support these computational 
findings, we believe that the various in-silico tools demonstrated in this report should serve as an 
initial step that could assist medicinal chemists to design more potential irreversible inhibitors.  
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Abstract 
Based on experimental data, the anticancer activity of FDA-approved HIV-1 protease 
inhibitors (PIs) were previously reported. Heat Shock Protein 90 has been identified as a 
known anticancer therapeutic target. The experimental data, which shows that nelfinavir has an 
anticancer inhibitory effect on yeast Hsp90, since it exhibited the highest IC50 value, raised the 
possibility that NFV might have the same effect on a mammalian Hsp90. The lack of the X-ray 
crystal structure of human Hsp90 makes the mechanism of binding of these drugs to the enzyme 
more ambiguous, especially with the existence of more than one possible binding domain in the 
Hsp90 enzyme. To this end, in this work, we embarked on various computational approaches to 
investigate the binding mode of the current FDA-approved HIV-1 PIs against Hsp90.  Since the 
X-ray crystal structure of the human Hsp90 protein is not yet resolved, homology modelling was 
performed to create its 3D structure for subsequent simulations. The two possible binding sites, 
C-terminal and N-terminal domains, were considered in this study. Eighteen 5ns molecular 
dynamic simulations and free binding energy calculations were carried out. Based on the 
thermodynamics calculations, it was found that these inhibitors are most likely to bind at the N-
terminal domain with a significant binding affinity difference (~ 54.7 -83.03 kcal/mol) when 
compared to C-terminal domain. To our knowledge, this is the first account of detailed 
computational investigations aimed to understand the binding mechanism of HIV PIs binding to 
Hsp90. Information gained from this study should also provide a route map towards the design 
and optimisation of potential derivatives of PIs to treat HER2+ breast cancer. 
Keywords: Binding free energy, molecular dynamics, HIV-1 protease inhibitors, anticancer  
 





Cancer, a heterogeneous disease, is one of the major cause of death worldwide (1) . In 2008, 
GLOBOCAN estimated about 12.7 million cancer cases and 7.6 million cancer deaths (about 
21,000 cancer deaths a day) occurrence; of these, 56% (2.8 million) of the cases and 64% (4.8 
million) of the deaths occurred in the economically developing countries (1). An estimated 14.1 
million cancer cases occurred in 2012 (2). In 2014, an estimated 585,720 cancer deaths is 
expected in the United States (3). According to the American Cancer Society, it has been 
reported that there remains an expected increase in the cancer incidences in the next twenty 
years, more especially in African regions (4, 5).  
Cancer is an abnormal proliferation of cells that can lead to malignancy and death. These cells 
have the potential to elude other normal cells through the process called metastasis (5). Causal 
factors like tobacco, chemicals, radiation, infectious organisms, inherited mutations and 
hormones may act together to initiate or accelerate carcinogenesis. Among the numerous types of 
cancer, breast cancer is the most common cancer diagnosed in women worldwide (6). 
Approximately two-thirds of breast cancer tumors are hormone dependent, requiring estrogens to 
grow and estrogens are formed in the human body via a multistep route starting from cholesterol 
(7).  
Estrogen receptor (ER) and human epidermal growth factor 2 (HER2) are familial hormone 
sensitive receptors of the human epidermal growth factor (EGFR). HER2 consists of four 
subtypes (HER1–4) (8); which are regulated at the level of expression by hormones; thus, HER2 
is of greatest significance as it is a pivotal receptor target for breast cancer treatment. Compared 
to other types of breast cancer, HER2+ breast cancer tends to be more aggressive and less 
receptive to hormone treatments. According to published data, it was documented that 
approximately 25–30% of human breast cancers overexpress HER2 (9, 10), in which heat shock 
protein (HSP) has been reported to play a role in the overexpression of HER2 (11, 12). 
Therefore, to block HER2 overexpression, the subsequent step would be to inhibit the enzyme 
responsible for producing this estrogen, Hsp90. Hsp90 functions as a molecular chaperone, 
regulating the proper functionality of other proteins in the body (13).  
Hsp90 is a homodimer consisting of  and  chains. Each monomer of Hsp90 dimer contains 
four domains: 1) a highly conserved N-terminal (NTD), 2) C-terminal domain (CTD), 3) a 




middle domain (MD), and 4) a charged linker that connects the N-terminal and middle domain 
(14) as shown in Figure 1.  
 
 
Figure 5.1: The crystal structure of Hsp90 Alpha (blue) and Beta chain (gold) (PDB code: 
2CG9) showing its different domains (15). 
 
Hsp90 contains a highly conserved ATP binding site near its NTD, as Hsp90 functions are 
energetically expensive (16). This Hsp90-ATP binding site has been under intense 
pharmaceutical investigation, as many designed drugs offer competitive inhibition against ATP 
for this site (14). The design, development and discovery of new cancer chemotherapeutics 
cannot meet the demand and rate at which the disease is manifesting. The devastating effects are 
evident from the high mortality rate of inflicted patients, due to progression of the disease or 
inherited infection contracted from having a compromised immunity. Recent studies projects that 
a more efficient procedure for drug development that reduces costs is to find new indications for 
already approved drugs; this process is referred to as ‘‘repositioning’’ (17-19). “Repositioning” 
takes advantage of available data on existing drugs, limits risks and costs to pharmaceutical 
companies, and could advance the evaluation and movement of new cancer therapies to the 
clinic.  
 




The study conducted by Shim et al., analyzed the proteolytic profile of yeast Hsp90α full length 
for both N- and C- terminal domains. This study identified five drugs that exhibited significant 
inhibitory potential on cell proliferation with the HER2+ breast cancer lines. These include: 
mercaptopurine, nelfinavir (NFV) mesylate, geftinib, triciribine, and 6-α-methylprednisolone. It 
was reported that four of the drugs, excluding NFV, offered negligible to relatively good 
inhibitory activity, and were thus discarded as viable therapeutics. Shim et al. reported the action 
of NFV in several breast cancer cell lines on a collection of yeast strain and identified Hsp90 as 
its target. The possibility that NFV had an anticancer effect on yeast raised the possibility that 
Hsp90 is the target of nelfinavir in mammalian cells. Shim et al further projected that since NFV 
has no effect on trypsin digestion of N- and middle domain of the Hsp90, it is likely that NFV 
binds to the Hsp90 C-terminal domain and induces conformational changes in the protein; which 
is a different mechanism from other Hsp90 inhibitors (20). A study performed by Peterson 
further affirm this assumption that the CTD, which is responsible for maintaining Hsp90 
functional homodimeric state and coordinating interactions with several Hsp90 co-chaperones, 
show some promising binding mechanism (14).  
 
A study presented by Srirangam et al. reported that another protease inhibitor, ritonavir, partially 
inhibit the functions of Hsp90 (21). Based on the findings from the studies performed by Shim et 
al. and Bernstein et al., the FDA-approved HIV-1 protease inhibitors (PIs) showed to be 
promising in the inhibition of cancer, which is distinct from their ability to inhibit HIV protease 
(20, 22).  
The study performed by Shim et al., however, have some limitations. Foremost, the precise 
mode of interaction between NFV and Hsp90 remains a mystery. Secondly, the objectivity and 
interpretation of experimental outcome on mammalian cells was not stated. The probability that 
other PIs will be as potent as NFV is uncertain. The lack of a full X-ray crystal structure of the 
human Hsp90 might have been an important factor that significantly contributed to ambiguity of 
the binding mechanism of these drugs. From the lack of information with regards to binding 
modes, specific binding mechanism and conformation prompted our extensive computational 
investigation in order to explore the exact binding modes of HIV PIs against the human Hsp90.  
In this work, a homology model for the human Hsp90 was built. Comparative MD simulations 
and binding free energy calculations for nine FDA-approved HIV PR inhibitors (Figure 2) at the 




two different binding domains of Hsp90, C-terminal domain (CTD) and N-terminal domain 
(NTD), were performed. A total of 18 MD simulations (5ns each) were performed (section 2.4 
holds more details on the MD simulation protocol) and post-dynamic analyses were also 
performed. The compilation of the computational and molecular modeling tools presented in this 
study could serve as powerful tools to understand protein structures and dynamics which could 
be incorporated in drug discovery, design, development, repositioning and optimization of 
potential Hsp90 inhibitors as anticancer agents.  
 
  















5.2. Computational Methodology 
5.2.1. Homology modeling of human Hsp90 protein structure 
 
Due to the absence of a full human crystal structure of Hsp90 that comprises both the NTD and 
CTD, the crystal structure of the human Hsp90 was modeled using the protein sequence obtained 
from Uniprot (Uniprot ID: P08238). The full human Hsp90 homologue was modeled by using 
three crystal structures of Hsp90 as templates: Hsp90 from saccharomyces cerevisiae (PDB 
Code: 2CG9), which contained the ATP bound in its active site; Hsp90 MD from homo sapiens 
(PDB Code: 3PRY) and Hsp90 CTD from Leishmania major (PDB Code: 3HJC). Homology 
modeling was performed using the Modeler Software version 9.1 (23) add-on in Chimera (24). 
Multiple sequence alignment was performed on CLUSTAW (25). The active site residues were 
determined using Chimera Multi-align Viewer and validated using the Site-Hound web program 
(26). The homology model of the human Hsp90 was energy minimized and equilibrated via 
molecular dynamics simulations (see section 2.4) and then used for subsequent simulations. 
The sequence of the target protein was uploaded unto PSIPRED V3.3 (27, 28) in order to obtain 
a predicted 3D secondary structure of the enzyme. Comparing the homologue to the predicted 
3D structure and assessment of the bond angles and torsional strain shows the validation of the 
homology model. A Ramachandran plot for the analyses of bond angles and torsional strain was 
generated using Maestro (29). MolProbity (30) result shows that 98% of all residues are in the 
favoured regions and >99.8% of all residues are in the allowed regions which leaves a list of 20 
outliers. The list shows that none of the active site residues are part of these outliers (See 
Supplementary Material-S2).  
5.2.2. Defining the active site residues in the Hsp90 homology model 
 
Two binding sites (NTD and CTD) are known to exist in the Hsp90 based on previous reports 
(14, 31). The binding site of the N-terminal domain includes: Leu43, Asn46, Lys53, Ile91, 
Asp97, Met93, Asn101, Ser108, Gly109, Phe133 and Thr179 (50). On the other hand, the C-
terminal active site residues were identified as Gln523, Val534, Ser535, Lys538, Thr595, 
Tyr596, Gly597, Trp598 and Met602 in reference to 2CG9 crystal structure (14). The positions 




of these active site residues were mapped in the corresponding human Hsp90β homologue to 
identify the NTD and CTD active site pockets for further docking and molecular dynamic 
simulations. 
 
5.2.2.1. N-terminal Domain (NTD)  
The Swiss-PDB Viewer (30) was used to align the human Hsp90 homologue within the crystal 
structure of the human Hsp90 NTD (PDB Code: 3PRY) that contain geldanamycin inhibitor 
where the active site residues were known (32, 33). Chimera software (34) was used to define the 
corresponding active site residues in the homology model. Figure 3 shows the human Hsp90-
nelfinavir interaction at the NTD. The NTD active site residues were found to be Leu43, Asn46, 
Lys53, Ile91, Asp97, Met93, Asn101, Ser108, Gly109, Phe133 and Thr179. 
5.2.2.2. C-terminal domain (CTD) 
Due to the lack of information on the active site residues for the CTD, the active site residues 
were obtained from the Site-Hound web software (26). Closest active residue to the binding 
pocket, as shown in figure 3, was selected and used for further modeling studies. The obtained 
active site residues for the human Hsp90 homologue CTD were Gln523, Val534, Ser535, 
Lys538, Thr595, Tyr596, Gly597, Trp598 and Met602. 
 











Figure 5.3: (A) Nelfinavir-human Hsp90 homologue interaction at the NTD (B) Nelfinavir-
human Hsp90 homologue interaction at the CTD. Major contributions are from the 
residues that exhibit hydrophobic interactions (in green bubbles). Each illustration for 
other ligands at both terminals is provided in the supplementary material-S3. 
 
 




5.2.3. Building Hsp90-HIV protease inhibitor complexes 
 
In this study, AutoDock 4.0 suite was used as molecular docking tool in order to carry out the 
docking simulations. AutoDock has been found to be able to locate docking modes that are 
consistent with X-ray crystal structures (35, 36). AutoDock helps to simulate interactions 
between substrates or drug candidates as ligands and their macromolecular receptors of known 
three dimensional structures, allowing ligand flexibility described to a full extent elsewhere (37). 
In our docking simulations, the human Hsp90 homologue was used for performing docking. We 
opted to run virtual screening to assign the binding modes of HIV-1 protease inhibitors against 
Hsp90. To this end, 9 HIV-1 protease inhibitors were retrieved from ZINC database (38) and 
docked into the NTD and CTD active sites of Hsp90 homologue using Autodock Vina software 
(39). The grid box was defined with the grid parameters being X= 22, Y= 22 and Z= 20 for the 
dimensions and X= -126, Y= -33 and Z= 110 for the center grid box at the N-terminal domain; 
and grid parameters being X= 16, Y= 22 and Z= 28 for the dimensions and X= -81, Y= -54 and 
Z= 56 for the center grid box in the C-terminal domain. The human Hsp90-HIV-1 protease 
inhibitor complexes were obtained and used for all subsequent methods performed in this study.  
 
5.2.4. Molecular Dynamics Simulations 
 
Hsp90-HIV-1 protease inhibitor complexes were simulated using the GPU version of the 
PMEMD engine provided with the AMBER 12 package (40, 41). GAFF force field parameters 
for Hsp90-HIV-1 protease inhibitor complexes were calculated by antechamber module of 
AMBER 12 package. Hydrogen atoms of the proteins were added using the Leap module in 
AMBER 12 (41). The human Hsp90-HIV-1 protease complexes were obtained using Chimera 
and were solvated in an octahedron box of TIP3PBOX water with buffering distance of 8 Å 
between the protein surface and the box boundary (42); assuming normal charge states of 
ionizable groups corresponding to pH 7, sodium (Na+) counter-ions were added to achieve 
charge neutrality and to mimic biological environment more closely. Cubic periodic boundary 
conditions were imposed and the long-range electrostatic interactions were treated with the 
particle-mesh Ewald method implemented in AMBER 12 with a non-bonding cut-off distance of 




10 Å.  The partial atomic charges for the ligand were obtained using “antechamber” (43) module 
of AMBER 12. Initial energy minimization, with a restraint potential of 500 kcal/molÅ2 applied 
to the solute, was carried out with the aid of the SANDER module of the AMBER 12 program 
using the steepest descent method in AMBER 12 for 1000 steps followed by conjugate gradient 
protocol for 2000 steps.   
 
Due to the lack of parameters needed for the ligand in the Cornell et al force field (44), the 
missing parameters were created. Optimization of the ligands are first performed at the HF/6-
31G* level with the Gaussian 03 package(45). The standard AMBER force field for bioorganic 
systems (ff03) (46) was used to define the topology and parameter files for the enzyme and 
protease inhibitors using “gaff” (47) based on the atom types of the force field model developed 
by Cornell et al (40). The entire system was freely minimized for 1000 iterations. Heating was 
performed for 50ps from 0 to 300 K with harmonic restraints of 5 kcal/mol Å2 using a Langevin 
thermostat with a coupling coefficient of 1/ps. The entire system was then equilibrated at 300 K 
with a 2fs time step in the NPT ensemble for 500 ps and Berendsen temperature coupling (48) 
was used to maintain a constant pressure at 1 bar. The SHAKE algorithm (49) was employed on 
all atoms so as to constrain the bonds of all hydrogen atoms. With no restraints imposed, a 
production run was performed for 5ns in an isothermal isobaric (NPT) ensemble using a 
Berendsen barostat with a target pressure of 1 bar and a pressure-coupling constant of 2ps for 
analysis of the energy stabilization and RMSD values of the complex.  The coordinate file was 
saved every 1ps and the trajectory was analyzed every 1ps using the Ptraj module implemented 
in AMBER 12.  
 
5.2.5. Thermodynamic Calculation 
 
The free binding energy of protease inhibitors (PIs) to the human Hsp90 homologue active site 
was analyzed by the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) method 
(50-53). A single trajectory approach was used with 5000 snapshots at 50 ps interval of each 
simulation. From each snapshot, free binding energy (ΔGbind) was computed from the following: 
ΔGbind = Gcomplex – Greceptor – Gligand                                      (1) 




ΔGbind = Egas + Gsol – TΔS                                                 (2) 
Egas = Eint + Evdw +Eele                 (3) 
Gsol = GGB + GSA              (4) 
GSA = γSASA             (5) 
Where Egas is the gas-phase energy; Eint is the internal energy; Eele and EvdW are the Coulomb and 
Van der Waals energies, respectively. Egas was calculated using the ff03 force field. Gsol is the 
solvation free energy and can be decomposed into polar and nonpolar contributions. GGB is the 
polar solvation contribution calculated by solving the GB equation. GSA is the nonpolar solvation 
contribution estimated by the solvent accessible surface area (SASA) and was determined using 
a water probe radius of 1.4 Å. The surface tension constant γ was set to 0.0072 kcal/(mol·Å2) 
(54). The T and S are the temperature and the total solute entropy, respectively. S was calculated 
by classical statistical thermodynamics, using normal mode analysis (55).
 
Normal mode analysis 
was carried out in the AMBER 12 normal mode (NMODE) module. Due to the high 
computational cost in the entropy calculation, 100 snapshots were extracted from the last 
equilibrated 5 ns trajectory of the simulation with 50 ps time intervals.  
To theoretically evaluate the reliability of the calculated ΔG values, the standard error (SE) of 
the calculated free binding energy was estimated by using equation 6, which is related to the 
number (N) of snapshots chosen for the calculations (37).  
 
SE = RMSF /N            (6) 
 
5.3. Results and Discussion 
5.3.1. The Human Hsp90 homology model 
 
In an effort to work with a human Hsp90 that is comprised of the middle domain (MD), C-
terminal domain (CTD) and N-terminal domain (NTD), a homology model of the human Hsp90β 
was generated. Using the Hsp90 from Saccharomyces cerevisiae (PDB Code: 2CG9), crystal 
structure of Hsp90 MD from Homo sapiens (PDB Code: 3PRY) and a crystal structure of Hsp90 




CTD from Leishmania major (PDB Code: 3HJC) as structural templates, an human Hsp90 
homologue was constructed using software “Modeller”9.1 (23). Structural similarity between the 
three proteins showed good identity in and around the active site, NTD, MD and CTD, with the 
majority of active site residues having nearly identical positions (Figure 4a). The sequences 
shared a 64.11% (2CG9), 97.39% (3PRY) and 60.14% (3HJC) similarity according to the Multi-




Figure 5.4: (A) Superimposed structures of the 2CG9 (gold), 3PRY (purple) and 3HGC 
(blue) and the generated human homologue sequence (green), (B) Generated homology 
model of the human Hsp90β. 
As docking is the most appropriate tool to provide better description of the binding theme of 
inhibitors (56, 57), molecular docking was performed to elucidate the binding mode of the 
human Hsp90 homologue and its inhibitors. To this end, docking of HIV-1 protease inhibitors 
was successfully undertaken giving an idea on how these inhibitors are positioned on the binding 
pocket on the NTD and CTD. Figure 5 shows docked structure of the human Hsp90 homologue 
in complex with NFV. Nine FDA-approved HIV-1 inhibitors were docked to the human Hsp90 
allowing for the construction of enzyme-ligand complexes. Interestingly, all the HIV-1 PIs 
showed better binding to the active site residues of the human Hsp90 homologue and were 
perfectly situated on the binding pocket of the human Hsp90 homologue NTD and CTD as how 
the known inhibitors of Hsp90 bind (33). 





Figure 5.5: The human Hsp90 homologue docked with NFV at (a) N-terminal domain and 
(b) C-terminal domain. 
 
5.3.2. Molecular Dynamics (MD) simulations 
The structural dynamics of all HIV-1 PIs, which are bound to the human Hsp90 homologue were 
analysed by performing 5ns molecular dynamics simulation (58-60) and free binding energy 
calculations (61, 62), which have proved to be very useful and successful in understanding the 
molecular basis of drug inhibition to different biological targets. It provides useful structural and 
energetic information about the interaction between the inhibitors and the targets. The system 
stability and overall convergence of simulations were monitored in terms of Root Mean-Square 
Deviation (RMSD), and potential energy of the protein backbone atoms. The RMSD and 








5.3.2.1. Post-dynamic analyses:  
Stability of Molecular Dynamics simulation 
As shown in figure 6, the system was well equilibrated where the RMSD value of all nine 
complexes at the NTD did not exceed 2Å and stabilised after 1000 ps.  On the other hand, the 
CTD shows that all the nine complexes did not exceed 2Å and stabilised after 1800 ps. The 
fluctuations of potential energies at the NTD were <2000 kcal/mol for the duration of 5 ns 
whereas the CTD had fluctuations in the potential energy of ≤ 8000 kcal/mol. Overall, it was 
observed that equilibration at NTD and CTD was achieved although they occurred at different 
time frames. 
The potential energy observed for the inhibitors at the CTD indicate that there is an initial energy 
increase that is due to the heating up of the system. A decrease in potential energy was observed 
followed by stabilization, implying that the system folded up to a state more stable than the 
starting linear structure. This trend was observed for all complexes at the CTD. 
 





Figure 5.6: Comparative RMSD and potential energy plot of all ligands binding at the N-
terminal domain and C-terminal domain respectively. (Individual plot for each ligand is 
provided in the supplementary material). 
RMSF calculations 
The root mean square fluctuations (RMSF) of the average structure from the trajectory report the 
residue and atomic fluctuations to check if the simulation results are in accordance with the 
crystal structure. Figure 7 shows the residue based RMSF of the NTD and CTD simulations. The 
amino acid residues in the region of 216-287 show higher fluctuation in both the NTD and CTD 
in comparison to the other amino acid residues which all exhibit lower fluctuations. It was 




observed that the amino acids in the region of 216-287 demonstrated no significant effect on how 
the human Hsp90 homologue interacted with the HIV-PIs at both terminals.  
 
Figure 5.7: (A) Comparative RMSF plot of all ligands binding at the N-terminal domain 
and (B) Comparative RMSF plot of all ligands binding at the C-terminal domain. 
(Individual plot for each ligand is provided under the supplementary material). 




5.3.2.2. MM/GBSA free binding energy calculations 
In the present study, we applied MM/GBSA as it has been demonstrated to be more efficient for 
protein-drug systems (63-65), carbohydrates (66) and nucleic acids (67). It utilizes a fully 
pairwise potential that is useful for decomposing the total binding free energy into atomic or 
group contributions (68). In addition, the MM/GBSA was successfully applied for ligand binding 
interactions with HIV PR with multidrug resistance (69-71). All components of molecular 
mechanics, solvation energy and free binding energies for the binding of the PIs (ΔGbind in 
kcal/mol) were calculated from the MD trajectories using the MM/GBSA method (50-53) 
implemented in AMBER 12 (41). This method explores the type of established interactions, 
calculating separately the components of the internal energy, the interaction energy and the free 
energy of Gibbs of solvation (72). 100 snapshots were extracted at a time interval of 10 ps from 
the 5ns of MD trajectories for the analysis of the binding free energy. MD simulations were used 
to examine the solvation of the binding pockets of the human Hsp90 homologue (NTD and 
CTD) in complex with the nine PIs. The values of the free binding energy presented in table 1 
show that for all the PIs, there is a higher binding in the NTD as compared to the CTD. The free 
binding energy of NFV being -83.03 kcal/mol at the NTD and -39.3 kcal/mol at the CTD. This 
value shows a significant difference (~43.73 kcal/mol) between the interaction energy at the 
NTD and CTD. Indinavir (IDV) on the other hand, gives the high value of the free binding 
energy of -67.3 kcal/mol, with an internal Van der Waal (Gvdw) energy of -81.3 kcal/mol at the 
NTD whereas there is a huge drop of the free binding energy (-9.7 kcal/mol) and Van der Waals 
energy (-41.8 kcal/mol) at the CTD. Such a great reduction in binding affinity (~57.6 kcal/mol) 
indicates relatively weaker ligand binding at the CTD. 
The major favourable contributions observed for the human Hsp90 homologue-PIs complexes 
free binding energies occur at the NTD which are significantly higher compared to the CTD. 
This trend is observed for all complexes except RTV which has a reasonably good free binding 
energy (-64.8 kcal/mol) at the NTD and (-63.9 kcal/mol) at the CTD with a difference of (~0.9 
kcal/mol) . There appears to be a probability that RTV has a good efficacy at both terminals and 














































































































































All energies of the NTD and CTD, with corresponding standard errors, are in kcal/mol.
 
b 
∆Egas =∆Eint+∆EvdW + ∆Gele 
c 
∆Gsol = ∆GSA + ∆GGB 
d
∆G bind =∆G gas +∆Gsol - T∆S 
 
Shim et al (2012) analyzed the activities of some drugs, which include mercaptopurine, 
nelfinavir mesylate, gefitinib, triciribine and 6-α-methylprednisolone, which showed least to 
relatively good selectivity for HER2+ breast cancer lines. The action of nelfinavir in HER2+ 
breast cancer cells was tested by screening a collection of yeast strains and acknowledged the 
Hsp90 protein as a potential target. In the study conducted by Shim, nelfinavir strongly inhibited 
certain HER2 signaling events and also had the highest potency (IC50 10μM), which suggests that 
it may be effective in HER2+ breast cancer patients with the same dosage regimen administered 
to HIV-1-infected patients (20). Based on Shim et al. study, it is clear that PIs inhibit a wide 




variety of malignant cell lines with nelfinavir having the best inhibition profile. Despite 
extensive experimental studies performed on the anticancer activity of NFV, the precise 
molecular and binding mechanism responsible for its inhibitory effect on either yeast or human 
Hsp90 remains anonymous. 
 
From Table 1, it is evident that nelfinavir binds readily to the human Hsp90 homologue NTD 
(ΔGbind -83.23 kcal/mol) which is in accordance with the experimental findings from the study 
conducted by Shim et al (20). This finding implies that the simulation protocol of this work is 
appropriate and reliable. 
In comparison to the CTD, the human Hsp90 NTD binding pocket was found more promising 
than the CTD binding pocket. According to the results of the ΔEvdW calculation, the NTD 
domain also showed higher Van der Waals interaction energies (ranging from -57.7 to -89.8 
kcal/mol), whereas the CTD showed lower interaction energies (ranging from -38.4 to -76.2 
kcal/mol). It was observed that other PIs showed better interaction to the NTD implying that the 
NTD might be the preferred domain for binding of PIs to the human Hsp90. The study 
performed by Shim et al., showed that nelfinavir inhibit Hsp90 at the site distinct from that of the 
known inhibitor (20). At this point, more studies are required to further verify the binding mode 
of the human Hsp90 CTD to HIV-1 PIs. 
 
5.3.2.3. Per-residue interaction energy decomposition analysis 
The binding free energy calculation was further performed to determine contributions from each 
human Hsp90β amino acid residue. It can be observed from the energy decomposition analysis at 
the NTD that the amino acid residues with major contributions were: Leu43, Asn46, Lys53, 
Ile91, Asn101, Ser108, Gly109, Met93, Phe133, Thr179 and those with minor contributions 
towards the interaction energy were residues Asp97, Val131, Val145, Val181 and Tyr134. At the 
CTD, the amino acid residues with major contributions were Gln523, Val534, Lys538, Ser535, 
Thr595, Tyr596, Trp598 and Met602 and those with minor contributions were Tyr485, Glu519, 
Val522, Gln524, Lys526, Leu533, Val534, Thr599 and Tyr619. These contributions can be due 
to their hydrophobicity nature as shown in figure 8. These trends were maintained in all 
complexes at both terminals.  
 





Figure 5.8: (A) Residues that contributed to the human Hsp90-nelfinavir binding at the 
NTD and (B) Residues contributing to the human Hsp90-nelfinavir binding at the CTD. 









In this study, the potential mechanism of binding of nine PIs to the human Hsp90β homologue at 
the NTD and CTD was investigated. Some active site residues have been identified in both 
terminals in previous studies and this brought about the investigation and validation of these 
theories by computational methods. These methods include: Virtual screening, Molecular 
dynamics (MD) simulation, binding free energy calculation using MM/GBSA method 
implemented in AMBER 12, potential energy, per-residue energy decomposition, RMSF and 
RMSD calculations. 
From the above investigation of the CTD and NTD of the human Hsp90 homologue binding to 
HIV-1 protease inhibitors, it can be concluded that these HIV-1 PIs interact better at the NTD 
than at the CTD. However, ritonavir has promising binding affinities at both terminals and 
should therefore be considered for experimental evaluation. Additionally, apart from ritonavir, 
saquinavir and nelfinavir; further investigation needs to be carried out on the CTD to look for 
more promising drugs that could bind to its active site residues. As at the time of this study, there 
was limited experimental information available regarding this domain. It was reported in 
previous studies that nelfinavir was found to be more potent than other PIs tested against breast 
line cell cancer, however, computationally, result shows that nelfinavir as well as other PIs may 




RMSF vs. time, RMSD vs. time and Potential Energy (kcal/mol) vs. time data for the human 
Hsp90 homologue in complex with HIV-1 PIs at both NTD and CTD, Per-residue decomposition 
at NTD and CTD; ligand-complex interaction at NTD and CTD; MolProbity result including all 
validation data are provided in the supplementary material. 
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This chapter presents general conclusions, recommendations as well as suggestions for future 
research. 
6.1. General Conclusion  
The main aim of this study was to investigate effective therapeutic drugs, using Cathepsin B and 
Hsp90 as our target enzymes that are involved in a variety of cancer pathological processes. The 
Michael acceptor-type compounds that show better covalent binding with Cathepsin B were 
investigated and drug binding modes and stability of the FDA-approved HIV-1 protease 
inhibitors to the target enzyme (Hsp90) binding sites so as to inhibit cancer were explored. The 
computational chemistry methods applied in this work provided a cost effective and an efficient 
tool for drug discovery and development. This research study has accomplished two practical 
aims of the study that resulted in the following conclusions: 
1. A unique workflow that involved hybrid ligand/structure based virtual screening using 
covalent docking approach to search for novel irreversible cathepsin B inhibitors based 
on Michael acceptor-like structures was exploited. We discovered ZINC03378824 to 
have the highest covalent binding affinity with Cathepsin B active site (Cys29) and other 
compounds with better binding affinity when compared to the experimental compounds 
including ZINC00477774, ZINC04901668 and ZINC04332083.   
2. The MD simulations result of the best hit compound (ZINC03378824) showed that all-
atom RSMD is below 1 Å, and the variation in the total potential energy is less than 1000 
kcal/mol, indicating that the interactions with the enzyme site were strong enough to 
maintain the ligand bonding, thus the system was quite stable. The amino acid residues 
that contributed the most to the binding of the top hit compound include  Cys26, Cys119, 
Gln23, Glu122, Gly27, His110, His199, Ser25, Trp30 and Trp221. The binding forces of 
these amino acid residues were analysed, and it was observed that polar interactions were 
the most prominent binding forces. Residues involved in such interaction were Cys26, 
Cys119, Gln23, Glu122, Gly27, His110, His199, Ser25, Trp30 and Trp221. Hydrophobic 
interactions were also observed between the ligand and Ala200, Ala173, Trp30, Trp221 
and Pro76 of the target enzyme.  An integrated computational workflow introduced in 




this study will serve as time-efficient powerful tool in the process of drug design and 
discovery of covalent inhibitors of Cathepsin B.  
3. The relevance of relative affinities between human HSP90 enzyme and HIV-1 protease 
inhibitors as part of the step-by-step process of drug design was established. The 
reference protein (PDB codes: 2CG9, 3PRY and 3HJC) crystal structures were used as 
templates to construct a human Hsp90β homologue. The Ramachandran plot showed that 
the validity of the human Hsp90 homologue was 98% of all residues, including the active 
site residues, which were in the favored region with 99.8% being in the allowed region. 
The binding pocket of the homologue in complex with HIV-1 protease inhibitors at both 
the NTD and CTD was investigated. Some active residues have been identified in both 
terminals in previous studies (1), and this formed the basis of investigating and validating 
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4. The convergence of post-dynamic simulation was validated by RMSD, RMSF and 
potential energy plots. The residue based RMSF shows that the amino acid residues in the 
region of 216-287 show higher fluctuation in both the NTD and CTD compared to the 
other amino acid residues, which all exhibit lower fluctuations. It was also observed that 
the amino acids in the mentioned region demonstrated no significant effect on how the 
human Hsp90 homologue interacted with the HIV-PIs at both terminals. 
5. The RMSDs of all the nine complexes at the NTD did not exceed 2Å and the system was 
stabilized after 1000 ps MD simulation, indicating that the system was well equilibrated. 
On the other hand, the CTD domain showed that all the nine complexes did not exceed 
2Å and the system stabilized after 1800 ps MD simulation. In addition, the fluctuations of 
potential energies at the NTD were <2000 kcal/mol for 5 ns of MD simulation and CTD 
show that the fluctuations of the potential energy to be ≤8000 kcal/mol. Overall, it is 
observed that equilibration at NTD and CTD was achieved, although they happen at 
different time frames. 
6. From the above results, it can be concluded that these HIV-1 PIs bind more at the NTD 
than the CTD. The active site residues responsible for binding at the NTD included: 
Leu43, Asn46, Lys53, Ile91, Asp97, Met93, Asn101, Ser108, Gly109, Phe133 and 
Thr179. Sufficient computational evidence has indicated that the NTD active residues 
show better binding to these nine PIs, thereby inhibiting cancer growth. However, the 




active site residues responsible for binding at the CTD include Gln523, Val534, Ser535, 
Lys538, Thr595, Tyr596, Gly597, Trp598 and Met602. It is therefore evident from these 
results that only few PIs such as RTV, LPV, APV, ATV and NFV bind successfully to 
the CTD at reasonable RMSD range value. Thus, this study suggests further investigation 
to be carried out on the CTD to identify more promising drugs that could bind to its 
active site residues and exhibit excellent pharmacokinetic and pharmacodynamics 
properties.  
6.2. Recommendations and Future Studies 
This study enabled the identification of potential Michael acceptor-type compounds that form 
irreversible binding with Cathepsin B, and with the mechanism of inhibition of HIV-1 protease 
inhibitors on Hsp90 also being explored, all for cancer eradication. However, further 
computational investigation will be necessary to understand enzyme-substrate interactions and 
structural evolution towards substrate binding. Quantum Mechanics implemented in this study 
could provide better insights into the molecular interactions regarding the distribution of motion 
by defining the behavior of nuclei and electrons within the enzyme-inhibitor complexes. It could 
also help to determine the nature of enzyme-inhibitor bond formation in order to improve our 
understanding into their binding mode (2, 3). Other advanced computational approaches that 
would be useful include Residue Interaction Network (RIN) (4), Principal Component Analysis 
(PCA) (5), Substrate Envelope Analysis (SEA) (6), Quantitative Structure-Activity Relationships 
(QSAR) (7), and coarse grained molecular dynamics (8) as they provide a better understanding 
of the enzyme dynamics during the catalytic course. In addition, further experimental testing 
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Appendix A1: Input files for docking the human cathepsin B complexes 
receptor = rec.pdbqt 
exhaustiveness = 8 
center_x = 33.9 
center_y = 34.1 
center_z = 32.9 
size_x = 34 
size_y = 42 
size_z = 48 
 
Appendix A2: Input files for docking the modelled human Hsp90 complexes at 
NTD  
receptor = rec.pdbqt 
exhaustiveness = 8 
center_x = -126.0 
center_y = -33.0 
center_z = 110.0 
size_x = 22 
size_y = 22 





Appendix A3: Input files for docking the modelled human Hsp90 complexes at 
CTD 
receptor = rec.pdbqt 
exhaustiveness = 8 
center_x = -81.0 
center_y = -54.0 
center_z = 56.0 
size_x = 16 
size_y = 22 
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The figure above shows the 2D sequence multi-alignment of Hsp90 from saccharomyces 
cerevisiae (PDB Code: 2CG9), which contained the ATP bound in its active site; Hsp90 middle 
domain from homo sapiens (PDB Code: 3PRY), Hsp90 C- terminal domain from Leishmania 






















Supplementary Figure-S3: Ligand-enzyme interaction at the human Hsp90 homologue 







































































Supplementary Figure-S4: Comparative per-residue decomposition energy at the human 
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